Etoposide

Identification

Name
Etoposide
Accession Number
DB00773  (APRD00239)
Type
Small Molecule
Groups
Approved
Description

A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. [PubChem]

Structure
Thumb
Synonyms
  • (−)-etoposide
  • 4-demethylepipodophyllotoxin β-D-ethylideneglucoside
  • 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
  • 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
  • Etoposido
  • Etoposidum
  • trans-Etoposide
External IDs
NSC-141540 / VP-16-213
Product Ingredients
IngredientUNIICASInChI Key
Etoposide Phosphate528XYJ8L1N 117091-64-2LIQODXNTTZAGID-OCBXBXKTSA-N
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Dom-etoposideLiquid20 mgIntravenousDominion PharmacalNot applicableNot applicableCanada
EposinLiquid20 mgIntravenousPharmachemie B.V.Not applicableNot applicableCanada
EtopophosInjection, powder, lyophilized, for solution100 mg/1IntravenousE.R. Squibb & Sons, L.L.C.2009-06-01Not applicableUs
EtoposideLiquid20 mgIntravenousPharmel IncNot applicableNot applicableCanada
Etoposide - Liq IV 20mg/mlLiquid20 mgIntravenousBdh Inc.1997-01-281998-07-01Canada
Etoposide InjectionLiquid20 mgIntravenousTeva1994-12-31Not applicableCanada
Etoposide InjectionLiquid20 mgIntravenousFresenius Kabi2014-10-20Not applicableCanada
Etoposide Injection USPSolution20 mgIntravenousSandoz Canada Incorporated2013-09-04Not applicableCanada
Etoposide Injection, USPLiquid20 mgIntravenousMylan Pharmaceuticals2014-07-10Not applicableCanada
Etoposide Injection, USPSolution20 mgIntravenousHospira, Inc.1999-12-28Not applicableCanada
PMS-etoposideLiquid20 mgIntravenousPharmascience IncNot applicableNot applicableCanada
VepesidCapsule50 mgOralBristol Myers Squibb1984-12-31Not applicableCanada
Vepesid Inj 20mg/mlLiquid20 mgIntravenousBristol Labs Division Of Bristol Myers Squibb1981-12-312007-10-30Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EtoposideInjection20 mg/mLIntravenousAccord Healthcare Limited2013-09-15Not applicableUs
EtoposideCapsule50 mg/1OralMylan Pharmaceuticals2001-10-22Not applicableUs
EtoposideInjection20 mg/mLIntravenousAccord Healthcare Limited2013-08-01Not applicableUs
EtoposideInjection, solution20 mg/mLIntravenousFresenius Kabi2001-07-18Not applicableUs
EtoposideInjection20 mg/mLIntravenousBlue Point Laboratories2013-11-14Not applicableUs
ToposarInjection, solution, concentrate20 mg/mLIntravenousTeva Parenteral Medicines, Inc.1996-08-01Not applicableUs
ToposarInjection, solution, concentrate20 mg/mLIntravenousTeva Parenteral Medicines, Inc.1996-08-012017-06-30Us
ToposarInjection, solution, concentrate20 mg/mLIntravenousTeva Parenteral Medicines, Inc.1997-05-012017-11-30Us
Approved Over the Counter Products
Not Available
Unapproved/Other Products
Not Available
International/Other Brands
Etopofos (Bristol-Myers Squibb) / Lastet (Cancernova) / Nexvep (Bristol-Myers Squibb) / Vepesid K (Bristol-Myers Squibb) / Vépéside (Novartis)
Brand mixtures
Not Available
Categories
UNII
6PLQ3CP4P3
CAS number
33419-42-0
Weight
Average: 588.5566
Monoisotopic: 588.18429111
Chemical Formula
C29H32O13
InChI Key
VJJPUSNTGOMMGY-MRVIYFEKSA-N
InChI
InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1
IUPAC Name
(10R,11R,15R,16S)-16-{[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0³,⁷.0¹¹,¹⁵]hexadeca-1,3(7),8-trien-12-one
SMILES

Pharmacology

Indication

For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Structured Indications
Pharmacodynamics

Etoposide is an antineoplastic agent and an epipodophyllotoxin (a semisynthetic derivative of the podophyllotoxins). It inhibits DNA topoisomerase II, thereby ultimately inhibiting DNA synthesis. Etoposide is cell cycle dependent and phase specific, affecting mainly the S and G2 phases. Two different dose-dependent responses are seen. At high concentrations (10 µg/mL or more), lysis of cells entering mitosis is observed. At low concentrations (0.3 to 10 µg/mL), cells are inhibited from entering prophase. It does not interfere with microtubular assembly. The predominant macromolecular effect of etoposide appears to be the induction of DNA strand breaks by an interaction with DNA-topoisomerase II or the formation of free radicals.

Mechanism of action

Etoposide inhibits DNA topoisomerase II, thereby inhibiting DNA re-ligation. This causes critical errors in DNA synthesis at the premitotic stage of cell division and can lead to apoptosis of the cancer cell. Etoposide is cell cycle dependent and phase specific, affecting mainly the S and G2 phases of cell division. Inhibition of the topoisomerase II alpha isoform results in the anti-tumour activity of etoposide. The drug is also capable of inhibiting the beta isoform but inhibition of this target is not associated with the anti-tumour activity. It is instead associated with the carcinogenic effect.

TargetActionsOrganism
ADNA topoisomerase 2-alpha
inhibitor
Human
NDNA topoisomerase 2-beta
inhibitor
Human
Absorption

Absorbed well, time to peak plasma concentration is 1-1.5 hrs. Mean bioavailability is 50% (range of 25% - 75%). Cmax and AUC values for orally administered etoposide capsules display intra- and inter-subject variability. There is no evidence of first-pass effect for etoposide.

Volume of distribution

The disposition of etoposide is a biphasic process with a distribution half-life of 1.5 hours. It does not cross into cerebrospinal fluid well. Volume of distribution, steady state = 18 - 29 L.

Protein binding

97% protein bound.

Metabolism

Primarily hepatic (through O-demethylation via the CYP450 3A4 isoenzyme pathway) with 40% excreted unchanged in the urine. Etoposide also undergoes glutathione and glucuronide conjugation which are catalyzed by GSTT1/GSTP1 and UGT1A1, respectively. Prostaglandin synthases are also responsible for the conversion of etoposide to O-demethylated metabolites (quinone).

Route of elimination

Etoposide is cleared by both renal and nonrenal processes, i.e., metabolism and biliary excretion. Glucuronide and/or sulfate conjugates of etoposide are also excreted in human urine. Biliary excretion of unchanged drug and/or metabolites is an important route of etoposide elimination as fecal recovery of radioactivity is 44% of the intravenous dose. 56% of the dose was in the urine, 45% of which was excreted as etoposide.

Half life

4-11 hours

Clearance
  • Total body clearance = 33 - 48 mL/min [IV administration, adults]
  • Mean renal clearance = 7 - 10 mL/min/m^2
Toxicity

Side effects include alopecia, constipation, diarrhea, nausea and vomiting and secondary malignancies (leukemia).

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Etoposide Metabolism PathwayDrug metabolism
Etoposide Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Etoposide can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Etoposide.Approved
AcenocoumarolEtoposide may increase the anticoagulant activities of Acenocoumarol.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Etoposide.Approved
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Etoposide.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Etoposide.Approved, Vet Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Etoposide.Approved
AlbendazoleThe serum concentration of Etoposide can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Etoposide can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Etoposide can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Etoposide can be increased when it is combined with Alfentanil.Approved, Illicit
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Etoposide.Approved, Investigational
AmantadineThe serum concentration of Etoposide can be increased when it is combined with Amantadine.Approved
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Etoposide.Approved, Investigational
Aminohippuric acidThe serum concentration of Etoposide can be increased when it is combined with Aminohippuric acid.Approved
AmiodaroneThe metabolism of Etoposide can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Etoposide.Approved
AmlodipineThe serum concentration of Etoposide can be increased when it is combined with Amlodipine.Approved
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Etoposide.Approved
AmprenavirThe serum concentration of Etoposide can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Etoposide can be increased when it is combined with Amsacrine.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Etoposide.Approved
AprepitantThe serum concentration of Etoposide can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Etoposide.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Etoposide.Approved, Investigational
AstemizoleThe serum concentration of Etoposide can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Etoposide can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Etoposide.Approved
AtomoxetineThe metabolism of Etoposide can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Etoposide can be increased when it is combined with Atorvastatin.Approved
AtovaquoneThe serum concentration of Etoposide can be increased when it is combined with Atovaquone.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Etoposide.Approved, Investigational
AzelastineThe serum concentration of Etoposide can be increased when it is combined with Azelastine.Approved
AzithromycinThe serum concentration of Etoposide can be increased when it is combined with Azithromycin.Approved
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Etoposide.Investigational
BenzocaineThe serum concentration of Etoposide can be increased when it is combined with Benzocaine.Approved
BepridilThe serum concentration of Etoposide can be increased when it is combined with Bepridil.Approved, Withdrawn
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Etoposide.Approved, Vet Approved
BevacizumabBevacizumab may increase the cardiotoxic activities of Etoposide.Approved, Investigational
BexaroteneThe serum concentration of Etoposide can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe serum concentration of Etoposide can be increased when it is combined with Biperiden.Approved
BoceprevirThe metabolism of Etoposide can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Etoposide can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Etoposide can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Etoposide.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Etoposide.Approved
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Etoposide.Approved, Investigational
BuprenorphineThe serum concentration of Etoposide can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe serum concentration of Etoposide can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Etoposide.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Etoposide.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Etoposide.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Etoposide.Approved
CandesartanThe serum concentration of Etoposide can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Etoposide can be increased when it is combined with Captopril.Approved
CarbamazepineThe serum concentration of Etoposide can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Etoposide.Approved
CarvedilolThe serum concentration of Etoposide can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Etoposide can be increased when it is combined with Caspofungin.Approved
CeritinibThe serum concentration of Etoposide can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Etoposide.Withdrawn
ChloroquineThe serum concentration of Etoposide can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Etoposide.Approved, Vet Approved
ChlorpropamideThe serum concentration of Etoposide can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Etoposide can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
CholesterolThe serum concentration of Etoposide can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Etoposide can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Etoposide can be increased when it is combined with Cilazapril.Approved
CimetidineThe serum concentration of Etoposide can be decreased when it is combined with Cimetidine.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Etoposide.Approved, Investigational
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Etoposide.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Etoposide.Approved
ClarithromycinThe metabolism of Etoposide can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Etoposide can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Etoposide.Approved, Illicit
ClofazimineThe serum concentration of Etoposide can be increased when it is combined with Clofazimine.Approved, Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Etoposide.Approved, Investigational
ClomipramineThe serum concentration of Etoposide can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Etoposide.Approved
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Etoposide.Approved, Nutraceutical
ClotrimazoleThe metabolism of Etoposide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Etoposide is combined with Clozapine.Approved
CobicistatThe metabolism of Etoposide can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Etoposide.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Etoposide.Approved
ColforsinThe serum concentration of Etoposide can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Etoposide can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Etoposide.Approved
CrizotinibThe metabolism of Etoposide can be decreased when combined with Crizotinib.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Etoposide.Approved, Investigational
CyclosporineThe metabolism of Etoposide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Etoposide can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Etoposide.Approved
DabrafenibThe serum concentration of Etoposide can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Etoposide can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Etoposide.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Etoposide.Approved
DarunavirThe metabolism of Etoposide can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Etoposide can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Etoposide can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Etoposide.Approved
DeferasiroxThe serum concentration of Etoposide can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Etoposide can be decreased when combined with Delavirdine.Approved
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Etoposide.Approved
DesipramineThe serum concentration of Etoposide can be increased when it is combined with Desipramine.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Etoposide.Approved
DesloratadineThe serum concentration of Etoposide can be increased when it is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Etoposide can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DextromethorphanThe serum concentration of Etoposide can be increased when it is combined with Dextromethorphan.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Etoposide.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Etoposide can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicoumarolEtoposide may increase the anticoagulant activities of Dicoumarol.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Etoposide.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Etoposide.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Etoposide.Approved
DihydroergotamineThe metabolism of Etoposide can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Etoposide.Illicit
DiltiazemThe metabolism of Etoposide can be decreased when combined with Diltiazem.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Etoposide.Approved
DisulfiramThe metabolism of Etoposide can be decreased when combined with Disulfiram.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Etoposide.Approved, Investigational
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Etoposide.Approved, Investigational, Vet Approved
DoxazosinThe serum concentration of Etoposide can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Etoposide can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Etoposide.Approved, Investigational
DoxorubicinThe serum concentration of Etoposide can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Etoposide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Etoposide can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Etoposide can be decreased when combined with Dronedarone.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Etoposide.Approved
EfavirenzThe serum concentration of Etoposide can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Etoposide can be increased when it is combined with Elbasvir.Approved
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Etoposide.Approved, Investigational
EltrombopagThe serum concentration of Etoposide can be increased when it is combined with Eltrombopag.Approved
EnalaprilThe serum concentration of Etoposide can be increased when it is combined with Enalapril.Approved, Vet Approved
EnzalutamideThe serum concentration of Etoposide can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Etoposide.Approved, Investigational
ErgonovineThe serum concentration of Etoposide can be increased when it is combined with Ergonovine.Approved
ErgotamineThe serum concentration of Etoposide can be increased when it is combined with Ergotamine.Approved
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Etoposide.Approved, Investigational
ErythromycinThe metabolism of Etoposide can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Etoposide can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Etoposide.Approved, Investigational, Vet Approved
EstramustineThe serum concentration of Etoposide can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Etoposide can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Etoposide can be decreased when it is combined with Estrone.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Etoposide.Approved
Ethyl biscoumacetateEtoposide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtravirineThe serum concentration of Etoposide can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Etoposide.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Etoposide.Approved
FelodipineThe serum concentration of Etoposide can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Etoposide can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Etoposide.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Etoposide.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Etoposide.Approved
FingolimodEtoposide may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
FluconazoleThe metabolism of Etoposide can be decreased when combined with Fluconazole.Approved
FluindioneEtoposide may increase the anticoagulant activities of Fluindione.Investigational
FluoxetineThe serum concentration of Etoposide can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe serum concentration of Etoposide can be increased when it is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Etoposide can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Etoposide can be increased when it is combined with Flurazepam.Approved, Illicit
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Etoposide.Approved
FluvoxamineThe metabolism of Etoposide can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Etoposide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Etoposide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Etoposide can be decreased when it is combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Etoposide can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Etoposide is combined with G17DT.Investigational
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Etoposide.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Etoposide.Approved
GenisteinThe serum concentration of Etoposide can be increased when it is combined with Genistein.Investigational
GI-5005The risk or severity of adverse effects can be increased when Etoposide is combined with GI-5005.Investigational
GlyburideThe serum concentration of Etoposide can be increased when it is combined with Glyburide.Approved
Gramicidin DThe serum concentration of Etoposide can be increased when it is combined with Gramicidin D.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Etoposide.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Etoposide.Withdrawn
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Etoposide.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Etoposide.Approved, Vet Approved
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Etoposide.Approved
IdelalisibThe serum concentration of Etoposide can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Etoposide can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Etoposide.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Etoposide.Approved
IndinavirThe metabolism of Etoposide can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Etoposide.Approved, Investigational
INGN 201The risk or severity of adverse effects can be increased when Etoposide is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Etoposide is combined with INGN 225.Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Etoposide.Approved, Investigational
IsavuconazoniumThe metabolism of Etoposide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Etoposide can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Etoposide can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Etoposide can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Etoposide can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Etoposide.Approved, Vet Approved
KetamineThe serum concentration of Etoposide can be increased when it is combined with Ketamine.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Etoposide.Approved
KetoconazoleThe metabolism of Etoposide can be decreased when combined with Ketoconazole.Approved, Investigational
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Etoposide.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Etoposide.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Etoposide.Approved, Investigational
LapatinibThe serum concentration of Etoposide can be increased when it is combined with Lapatinib.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Etoposide.Approved
LeflunomideThe risk or severity of adverse effects can be increased when Etoposide is combined with Leflunomide.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Etoposide.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Etoposide.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Etoposide.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Etoposide.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Etoposide.Approved
LevothyroxineThe serum concentration of Etoposide can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Etoposide can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Etoposide.Approved
LiothyronineThe serum concentration of Etoposide can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Etoposide can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Etoposide can be increased when it is combined with Lisinopril.Approved, Investigational
LomitapideThe serum concentration of Etoposide can be increased when it is combined with Lomitapide.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Etoposide.Approved
LopinavirThe metabolism of Etoposide can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Etoposide can be increased when it is combined with Loratadine.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Etoposide.Approved
LovastatinThe metabolism of Etoposide can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Etoposide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Etoposide can be decreased when it is combined with Lumacaftor.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Etoposide.Approved, Investigational
MaprotilineThe serum concentration of Etoposide can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Etoposide can be increased when it is combined with Mebendazole.Approved, Vet Approved
MefloquineThe serum concentration of Etoposide can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Etoposide can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MeprobamateThe serum concentration of Etoposide can be increased when it is combined with Meprobamate.Approved, Illicit
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Etoposide.Withdrawn
MethadoneThe serum concentration of Etoposide can be increased when it is combined with Methadone.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Etoposide.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Etoposide.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Etoposide.Approved, Investigational
MexiletineThe metabolism of Etoposide can be decreased when combined with Mexiletine.Approved
MibefradilThe serum concentration of Etoposide can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Etoposide can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Etoposide can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneThe serum concentration of Etoposide can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Etoposide.Approved
MitomycinThe serum concentration of Etoposide can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Etoposide can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Etoposide can be decreased when it is combined with Mitoxantrone.Approved, Investigational
ModafinilThe serum concentration of Etoposide can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Morphine can be increased when it is combined with Etoposide.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Etoposide.Approved, Investigational
NadololThe serum concentration of Nadolol can be increased when it is combined with Etoposide.Approved
NafcillinThe serum concentration of Etoposide can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Etoposide.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Etoposide.Approved, Vet Approved
NaltrexoneThe serum concentration of Etoposide can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Etoposide can be increased when it is combined with Naringenin.Experimental
NatalizumabThe risk or severity of adverse effects can be increased when Etoposide is combined with Natalizumab.Approved, Investigational
NefazodoneThe metabolism of Etoposide can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Etoposide can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Etoposide can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Etoposide can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Etoposide can be decreased when it is combined with Nevirapine.Approved
NicardipineThe serum concentration of Etoposide can be increased when it is combined with Nicardipine.Approved
NicotineThe metabolism of Etoposide can be decreased when combined with Nicotine.Approved
NifedipineThe serum concentration of Etoposide can be decreased when it is combined with Nifedipine.Approved
NilotinibThe metabolism of Etoposide can be decreased when combined with Nilotinib.Approved, Investigational
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Etoposide.Approved
NisoldipineThe serum concentration of Etoposide can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Etoposide can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Etoposide can be increased when it is combined with Nitrendipine.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Etoposide.Approved
NorethisteroneThe serum concentration of Etoposide can be decreased when it is combined with Norethisterone.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Etoposide.Approved, Investigational
OlaparibThe metabolism of Etoposide can be decreased when combined with Olaparib.Approved
OleandrinAnvirzel may decrease the cardiotoxic activities of Etoposide.Experimental
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Etoposide.Approved
OmeprazoleThe serum concentration of Etoposide can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OsimertinibThe serum concentration of Etoposide can be increased when it is combined with Osimertinib.Approved
OuabainOuabain may decrease the cardiotoxic activities of Etoposide.Approved
P-NitrophenolThe serum concentration of Etoposide can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Etoposide.Approved, Vet Approved
PalbociclibThe serum concentration of Etoposide can be increased when it is combined with Palbociclib.Approved
Palmitic AcidThe serum concentration of Etoposide can be increased when it is combined with Palmitic Acid.Experimental
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Etoposide.Approved, Investigational
PantoprazoleThe serum concentration of Etoposide can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe serum concentration of Etoposide can be increased when it is combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Etoposide.Approved
Peginterferon alfa-2bThe serum concentration of Etoposide can be increased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe serum concentration of Etoposide can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe serum concentration of Etoposide can be increased when it is combined with Perindopril.Approved
PhenindioneEtoposide may increase the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe serum concentration of Etoposide can be decreased when it is combined with Phenobarbital.Approved
PhenprocoumonEtoposide may increase the anticoagulant activities of Phenprocoumon.Approved
PhenytoinThe serum concentration of Etoposide can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Etoposide.Approved, Investigational
PimozideThe serum concentration of Etoposide can be increased when it is combined with Pimozide.Approved
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Etoposide.Approved
Platelet Activating FactorThe serum concentration of Etoposide can be decreased when it is combined with Platelet Activating Factor.Experimental
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Etoposide.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Etoposide.Approved
PosaconazoleThe metabolism of Etoposide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Etoposide.Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Etoposide.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Etoposide.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Etoposide.Approved, Vet Approved
PrimidoneThe serum concentration of Etoposide can be decreased when it is combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Etoposide can be increased when it is combined with Probenecid.Approved
ProgesteroneThe serum concentration of Etoposide can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromethazineThe serum concentration of Etoposide can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Etoposide can be increased when it is combined with Propafenone.Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Etoposide.Approved, Investigational
ProtriptylineThe serum concentration of Etoposide can be increased when it is combined with Protriptyline.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Etoposide.Approved
QuercetinThe serum concentration of Etoposide can be increased when it is combined with Quercetin.Experimental
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Etoposide.Approved
QuinacrineThe serum concentration of Etoposide can be increased when it is combined with Quinacrine.Approved
QuinidineThe serum concentration of Etoposide can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Etoposide.Approved
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Etoposide is combined with Rabies vaccine.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Etoposide.Approved
RanitidineThe serum concentration of Etoposide can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Etoposide.Approved, Investigational
ReboxetineThe serum concentration of Etoposide can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Etoposide can be increased when it is combined with Regorafenib.Approved
ReserpineThe serum concentration of Etoposide can be decreased when it is combined with Reserpine.Approved
RifabutinThe serum concentration of Etoposide can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Etoposide can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Etoposide can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Etoposide.Approved, Investigational
RilpivirineThe serum concentration of Etoposide can be increased when it is combined with Rilpivirine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Etoposide is combined with CDX-110.Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Etoposide.Approved, Investigational
RitonavirThe metabolism of Etoposide can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Etoposide.Approved
RoflumilastRoflumilast may increase the immunosuppressive activities of Etoposide.Approved
RolapitantThe serum concentration of Etoposide can be increased when it is combined with Rolapitant.Approved
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Etoposide.Approved, Investigational
RopiniroleThe metabolism of Etoposide can be decreased when combined with Ropinirole.Approved, Investigational
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Etoposide.Approved, Vet Approved
SaquinavirThe metabolism of Etoposide can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Etoposide.Approved
ScopolamineThe serum concentration of Etoposide can be increased when it is combined with Scopolamine.Approved
SelegilineThe serum concentration of Etoposide can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Etoposide.Approved
SertralineThe serum concentration of Etoposide can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Etoposide can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Etoposide.Approved
SiltuximabThe serum concentration of Etoposide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Etoposide can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Etoposide can be increased when it is combined with Simvastatin.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Etoposide.Approved
SirolimusThe serum concentration of Etoposide can be decreased when it is combined with Sirolimus.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Etoposide.Approved, Investigational
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Etoposide.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Etoposide.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Etoposide.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Etoposide.Experimental
SpironolactoneThe serum concentration of Etoposide can be increased when it is combined with Spironolactone.Approved
SRP 299The risk or severity of adverse effects can be increased when Etoposide is combined with SRP 299.Investigational
St. John's WortThe serum concentration of Etoposide can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Etoposide can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Etoposide can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Etoposide can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Etoposide can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleThe metabolism of Etoposide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Etoposide can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Etoposide can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Etoposide can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Etoposide.Approved, Investigational
TacrolimusThe serum concentration of Etoposide can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of Etoposide can be decreased when it is combined with Tamoxifen.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Etoposide.Experimental
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Etoposide.Approved
TelaprevirThe metabolism of Etoposide can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Etoposide can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Etoposide can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Etoposide.Approved
Tenofovir disoproxilThe metabolism of Etoposide can be decreased when combined with Tenofovir.Approved, Investigational
TerazosinThe serum concentration of Etoposide can be increased when it is combined with Terazosin.Approved
TerfenadineThe serum concentration of Etoposide can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideThe serum concentration of Etoposide can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe serum concentration of Etoposide can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Etoposide can be increased when it is combined with Testosterone.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Etoposide is combined with TG4010.Investigational
TheophyllineThe metabolism of Etoposide can be decreased when combined with Theophylline.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Etoposide.Approved
TiclopidineThe metabolism of Etoposide can be decreased when combined with Ticlopidine.Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Etoposide.Approved
TocilizumabThe serum concentration of Etoposide can be decreased when it is combined with Tocilizumab.Approved
TofacitinibEtoposide may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Etoposide.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Etoposide.Approved, Investigational
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Etoposide.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Etoposide.Approved, Investigational
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Etoposide.Approved
TrazodoneThe serum concentration of Etoposide can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Etoposide can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Etoposide can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Etoposide can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Etoposide can be increased when it is combined with Trimipramine.Approved
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Etoposide.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Etoposide.Approved
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Etoposide.Approved
VemurafenibThe serum concentration of Etoposide can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Etoposide.Approved
VenlafaxineThe metabolism of Etoposide can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Etoposide can be decreased when combined with Verapamil.Approved
VinblastineThe serum concentration of Etoposide can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Etoposide.Approved, Investigational
VincristineThe serum concentration of Etoposide can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Etoposide can be increased when it is combined with Vinorelbine.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Etoposide.Approved
VoriconazoleThe metabolism of Etoposide can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinEtoposide may increase the anticoagulant activities of Warfarin.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Etoposide.Approved
ZimelidineThe serum concentration of Etoposide can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Etoposide can be decreased when combined with Ziprasidone.Approved
Food Interactions
  • Grapefruit and grapefruit juice should be avoided throughout treatment as grapefruit can decrease serum levels of this product.

References

Synthesis Reference
US3524844
General References
  1. Zhou Z, Zwelling LA, Ganapathi R, Kleinerman ES: Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta. Br J Cancer. 2001 Sep 1;85(5):747-51. [PubMed:11531262 ]
  2. Azarova AM, Lyu YL, Lin CP, Tsai YC, Lau JY, Wang JC, Liu LF: Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11014-9. Epub 2007 Jun 19. [PubMed:17578914 ]
External Links
Human Metabolome Database
HMDB14911
KEGG Drug
D00125
KEGG Compound
C01576
PubChem Compound
36462
PubChem Substance
46505434
ChemSpider
33510
BindingDB
50127140
ChEBI
4911
ChEMBL
CHEMBL44657
Therapeutic Targets Database
DAP000786
PharmGKB
PA449552
HET
EVP
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Etoposide
ATC Codes
L01CB01 — Etoposide
AHFS Codes
  • 10:00.00
PDB Entries
Not Available
FDA label
Download (206 KB)
MSDS
Download (24.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentAdult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Contiguous Stage II Adult Burkitt Lymphoma / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Adult Lymphoblastic Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Burkitt Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Adult Lymphoblastic Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Adult Burkitt Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Adult Lymphoblastic Lymphoma / Stage I Adult T-Cell Leukemia/Lymphoma / Stage I Childhood Anaplastic Large Cell Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Lymphoblastic Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage IA Mycosis Fungoides/Sezary Syndrome / Stage IB Mycosis Fungoides/Sezary Syndrome / Stage II Adult Hodgkin Lymphoma / Stage II Adult T-Cell Leukemia/Lymphoma / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Lymphoblastic Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage IIA Mycosis Fungoides/Sezary Syndrome / Stage IIB Mycosis Fungoides/Sezary Syndrome / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Adult T-Cell Leukemia/Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IIIA Mycosis Fungoides/Sezary Syndrome / Stage IIIB Mycosis Fungoides/Sezary Syndrome / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Adult T-Cell Leukemia/Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Hodgkin Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Stage IVA Mycosis Fungoides/Sezary Syndrome / Stage IVB Mycosis Fungoides/Sezary Syndrome / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
0CompletedTreatmentPrecursor Cell Lymphoblastic Leukemia-Lymphoma1
0RecruitingTreatmentBrain Tumor Recurrent1
0TerminatedTreatmentAllogeneic peripheral haematopoietic stem cell transplant / Neuroepithelial Tumor / Tumors, Solid1
0TerminatedTreatmentLymphoma, B-Cell1
1Active Not RecruitingTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Recurrent Non-small Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
1Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Promyelocytic Leukemia With PML-RARA / Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA / Alkylating Agent-Related Acute Myeloid Leukemia / Recurrent Adult Acute Myeloid Leukemia / Refractory Acute Myeloid Leukemia1
1Active Not RecruitingTreatmentB-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma / B-Cell Prolymphocytic Leukemia / Post-Transplant Lymphoproliferative Disorder / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Lymphoplasmacytic Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia1
1Active Not RecruitingTreatmentBurkitt's Lymphoma / Follicular Lymphoma (FL) / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1Active Not RecruitingTreatmentCD20 Positive / Recurrent Diffuse Large B-Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma1
1Active Not RecruitingTreatmentLeukemias1
1Active Not RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
1Active Not RecruitingTreatmentLymphoma, B-Cell / Malignant Lymphomas1
1Active Not RecruitingTreatmentMalignant Lymphomas1
1Active Not RecruitingTreatmentMultiple Myeloma (MM) / Plasma Cell Neoplasms1
1Active Not RecruitingTreatmentNeuroblastomas1
1Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1Active Not RecruitingTreatmentRecurrent Adult Acute Myeloid Leukemia / Refractory Acute Myeloid Leukemia1
1CompletedPreventionLeukemias / Multiple Myeloma (MM)1
1CompletedSupportive CareCancers1
1CompletedTreatmentAML / CML / Leukemias / Myeloid Leukemias1
1CompletedTreatmentAccelerated Phase Chronic Myelogenous Leukemia / Adult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Acute Promyelocytic Leukemia (M3) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative / Blastic Phase Chronic Myelogenous Leukemia / Chronic Eosinophilic Leukemia (CEL) / Chronic Myelomonocytic Leukemia / Chronic Neutrophilic Leukemia / De Novo Myelodysplastic Syndromes / Essential Thrombocythemia (ET) / Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable / Polycythemia Vera (PV) / Previously Treated Myelodysplastic Syndromes / Primary Myelofibrosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Relapsing Chronic Myelogenous Leukemia / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes1
1CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Chronic Myelogenous Leukemia (CML) / Juvenile Myelomonocytic Leukemia / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentAcute Lymphoid Leukemia Relapse / Acute Lymphoid Leukemia Relapse After Bone Marrow Transplant1
1CompletedTreatmentAcute Myelogenous Leukaemia (AML)1
1CompletedTreatmentAcute Myeloid Leukaemias (AML) / Acute Myeloid Leukemia With Multilineage Dysplasia Following / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Myelodysplastic Syndrome / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
1CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1CompletedTreatmentBrain and Central Nervous System Tumors / Malignant Lymphomas / Neuroblastomas / Retinoblastoma1
1CompletedTreatmentCancer, Advanced / Metastatic Brain Tumors / Neuroectodermal Tumors1
1CompletedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1CompletedTreatmentCancers1
1CompletedTreatmentCarcinoma Neuroendocrine / Malignant Epithelial Neoplasms / Small Cell Lung Carcinoma1
1CompletedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Precancerous/Nonmalignant Condition / Small Intestine Cancer1
1CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1CompletedTreatmentExtensive Stage Small Cell Lung Cancer1
1CompletedTreatmentExtensive Stage Small Cell Lung Cancer / Unspecified Adult Solid Tumor, Protocol Specific2
1CompletedTreatmentGlioblastomas / Gliosarcoma1
1CompletedTreatmentHodgkins Disease (HD) / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)1
1CompletedTreatmentLeukaemia, Acute / Lymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
1CompletedTreatmentLeukemias4
1CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes2
1CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
1CompletedTreatmentLeukemias / Myelodysplastic Syndromes1
1CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
1CompletedTreatmentLung Cancers4
1CompletedTreatmentLymphoblastic Leukemia, Acute, Childhood1
1CompletedTreatmentLymphoblastic Leukemia, Acute, Childhood / Myelogenous Leukemia, Acute, Childhood1
1CompletedTreatmentLymphoma, Hodgkins / Malignant Lymphomas1
1CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1CompletedTreatmentMalignant Diseases1
1CompletedTreatmentMalignant Lymphomas3
1CompletedTreatmentMalignant Lymphomas / Sarcomas1
1CompletedTreatmentNeoplasms, Brain / Neuroblastomas / Sarcomas / Tumors, Central Nervous System1
1CompletedTreatmentNeoplasms, Brain / Tumors, Central Nervous System2
1CompletedTreatmentNeuroblastomas4
1CompletedTreatmentNon-Squamous Non-Small Cell Lung Cancer1
1CompletedTreatmentSarcomas1
1CompletedTreatmentSmall Cell Lung Carcinoma1
1CompletedTreatmentTumors, Solid1
1CompletedTreatmentUnspecified Adult Solid Tumor, Protocol Specific4
1Not Yet RecruitingTreatmentBeta-Thalassemia1
1Not Yet RecruitingTreatmentCD20 Positive / HIV Positivity / Lymphoma, AIDS Related / Stage II Diffuse Large B-Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma1
1Not Yet RecruitingTreatmentStage IIIA Non-Small Cell Lung Cancer1
1RecruitingTreatmentAML Arising After Exposure to Genotoxic Injury / AML Arising From Antecedent Hematologic Disorder (AHD) / AML Arising From Myelodysplastic Syndrome (MDS) / Newly Diagnosed Acute Myeloid Leukemia (AML) / Untreated AML1
1RecruitingTreatmentAbdominal wall neoplasm / Carcinoma, Squamous Cell of Head and Neck / Esophagogastric Junction Neoplasms / Fallopian Tube Neoplasms / Neoplasms, Ovarian / Small Cell Lung Carcinoma / Stomach Neoplasms / Triple Negative Breast Neoplasms1
1RecruitingTreatmentAcute Myelogenous Leukaemia (AML)2
1RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Blasts 10-19 Percent of Bone Marrow Nucleated Cells / Blasts 20 Percent or More of Bone Marrow Nucleated Cells / Blasts 5-19 Percent of Peripheral Blood White Cells / Chronic Myelomonocytic Leukemia-2 / Myelodysplastic Syndrome / Myeloproliferative Neoplasms / Previously Treated Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia1
1RecruitingTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
1RecruitingTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia1
1RecruitingTreatmentAdult Burkitt Lymphoma / Adult Diffuse Large B-Cell Lymphoma / CD20-Positive Neoplastic Cells Present / Indolent Adult Non-Hodgkin Lymphoma / Mantle Cell Lymphoma (MCL) / Recurrent B-Cell Non-Hodgkin Lymphoma / Refractory Mature B-Cell Non-Hodgkin Lymphoma1
1RecruitingTreatmentAdvanced Solid Tumors1
1RecruitingTreatmentAnaplastic Astrocytoma (AA) / Astrocytomas / Glioblastomas / Gliomas / Mixed Gliomas / Oligoastrocytoma, Mixed / Oligodendrogliomas / Optic Nerve Glioma / Pilocytic Astrocytoma1
1RecruitingTreatmentCastration-Resistant Prostate Carcinoma / Leukemia, Plasma Cell / Prostate Carcinoma Metastatic in the Bone / Recurrent Plasma Cell Myeloma / Stage IV Prostate Cancer1
1RecruitingTreatmentDisseminated Sclerosis1
1RecruitingTreatmentHigh Grade B-cell Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1RecruitingTreatmentHigh-risk Tumor / Malignant Lymphomas / Neuroblastomas1
1RecruitingTreatmentLeukemias / Pediatric Leukemia / Pediatric Solid Tumors1
1RecruitingTreatmentLeukemias / Refractory Solid Tumors / Relapsed Solid Tumors1
1RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
1RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC) / Non-Small-Cell Lung Carcinoma (NSCLC) / Tumors, Solid1
1RecruitingTreatmentLung Cancers1
1RecruitingTreatmentLymphoblastic Leukemia, Acute, Childhood / Lymphoma, Lymphoblastic / Peripheral T-Cell Lymphoma (PTCL)1
1RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
1RecruitingTreatmentMature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma / Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma / Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma1
1RecruitingTreatmentRecurrent Adult Hodgkin's Lymphoma1
1SuspendedTreatmentCancers1
1TerminatedTreatmentAcute Myeloid Leukaemias (AML)1
1TerminatedTreatmentAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome / Adult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Megakaryoblastic Leukemia / Adult Acute Monoblastic Leukemia / Adult Acute Monocytic Leukemia / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With Maturation / Adult Acute Myeloid Leukemia With Minimal Differentiation / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Adult Acute Myeloid Leukemia Without Maturation / Adult Acute Myelomonocytic Leukemia / Adult Erythroleukemia / Adult Pure Erythroid Leukemia / Alkylating Agent-Related Acute Myeloid Leukemia / Recurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
1TerminatedTreatmentAdenocarcinoma of the Lung / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
1TerminatedTreatmentAngioimmunoblastic T-Cell Lymphoma / B-cell Childhood Acute Lymphoblastic Leukemia / B-Cell Chronic Lymphocytic Leukemia / Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Grade III Lymphomatoid Granulomatosis / Childhood Immunoblastic Large Cell Lymphoma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / T-cell Childhood Acute Lymphoblastic Leukemia / T-Cell Large Granular Lymphocyte Leukemia / Unspecified Childhood Solid Tumor, Protocol Specific1
1TerminatedTreatmentBone Cancer / Kidney Tumors / Neoplasms / Neuroblastomas / Tumors, Solid1
1TerminatedTreatmentBone Marrow Suppression / Brain and Central Nervous System Tumors / Drug/Agent Toxicity by Tissue/Organ / Long-Term Effects Secondary to Cancer Therapy in Children1
1TerminatedTreatmentBrain and Central Nervous System Tumors / Liver Cancer / Renal Cancers / Retinoblastoma / Sarcomas1
1TerminatedTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1TerminatedTreatmentLeukemia, Myeloid, Acute1
1TerminatedTreatmentLeukemias1
1TerminatedTreatmentLung Cancer Metastatic / Sarcoma, Osteogenic1
1TerminatedTreatmentLung Cancers / Unspecified Adult Solid Tumor, Protocol Specific1
1TerminatedTreatmentLymphoma, B-Cell / Non-Hodgkin's Lymphoma (NHL)1
1TerminatedTreatmentNeoplasms1
1TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1TerminatedTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIB Non-small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
1Unknown StatusTreatmentBrain and Central Nervous System Tumors / Cancer, Ovarian / Childhood Germ Cell Tumor / Extragonadal Germ Cell Tumor / Liver Cancer / Neuroblastomas / Sarcomas / Testicular germ cell tumour1
1Unknown StatusTreatmentLeukemias / Malignant Lymphomas1
1Unknown StatusTreatmentLung Cancers1
1Unknown StatusTreatmentUnspecified Childhood Solid Tumor, Protocol Specific1
1WithdrawnTreatmentCancer, Breast / Lung Cancers / Melanoma (Skin) / Renal Cancers / Testicular germ cell tumour1
1WithdrawnTreatmentLeukemias / Malignant Lymphomas / Pediatric Disorders / Transplantation, Stem Cell1
1WithdrawnTreatmentLung Cancers2
1WithdrawnTreatmentUnspecified Adult Solid Tumor, Protocol Specific1
1, 2Active Not RecruitingTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Plasmablastic Lymphoma / AIDS-Related Primary Effusion Lymphoma / CD20 Positive / Grade 3b Follicular Lymphoma / Human Immunodeficiency Virus (HIV) Infections / Plasmablastic Lymphoma / Primary Effusion Lymphomas / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Diffuse Large B-Cell Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage II Contiguous Adult Diffuse Large Cell Lymphoma / Stage II Diffuse Large B-Cell Lymphoma / Stage II Grade 3 Contiguous Follicular Lymphoma / Stage II Grade 3 Non-Contiguous Follicular Lymphoma / Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma / Stage IV Grade 3 Follicular Lymphoma1
1, 2Active Not RecruitingTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Blastic Phase Chronic Myelogenous Leukemia / Childhood Acute Myeloid Leukemia in Remission / Childhood Chronic Myelogenous Leukemia / Childhood Myelodysplastic Syndromes / Previously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Refractory Anemia With Excess Blasts1
1, 2Active Not RecruitingTreatmentAdult Grade III Lymphomatoid Granulomatosis / B-Cell Chronic Lymphocytic Leukemia / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Contiguous Stage II Grade 1 Follicular Lymphoma / Contiguous Stage II Grade 2 Follicular Lymphoma / Contiguous Stage II Grade 3 Follicular Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Contiguous Stage II Marginal Zone Lymphoma / Contiguous Stage II Small Lymphocytic Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma / Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma / Noncontiguous Stage II Grade 1 Follicular Lymphoma / Noncontiguous Stage II Grade 2 Follicular Lymphoma / Noncontiguous Stage II Grade 3 Follicular Lymphoma / Noncontiguous Stage II Mantle Cell Lymphoma / Noncontiguous Stage II Marginal Zone Lymphoma / Noncontiguous Stage II Small Lymphocytic Lymphoma / Progressive Hairy Cell Leukemia, Initial Treatment / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage 0 Chronic Lymphocytic Leukemia / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Adult Diffuse Mixed Cell Lymphoma / Stage I Adult Diffuse Small Cleaved Cell Lymphoma / Stage I Adult Hodgkin Lymphoma / Stage I Adult Immunoblastic Large Cell Lymphoma / Stage I Chronic Lymphocytic Leukemia / Stage I Grade 1 Follicular Lymphoma / Stage I Grade 2 Follicular Lymphoma / Stage I Grade 3 Follicular Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Marginal Zone Lymphoma / Stage I Small Lymphocytic Lymphoma / Stage II Adult Hodgkin Lymphoma / Stage II Chronic Lymphocytic Leukemia / Stage II Small Lymphocytic Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Hodgkin Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Chronic Lymphocytic Leukemia / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Hodgkin Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Chronic Lymphocytic Leukemia / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Small Lymphocytic Lymphoma / Testicular Lymphoma / Untreated Hairy Cell Leukemia / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / B-cell Adult Acute Lymphoblastic Leukemia / B-Cell Chronic Lymphocytic Leukemia / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent B-Cell Non-Hodgkin Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Hodgkin Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Recurrent T-Cell Non-Hodgkin Lymphoma / Refractory B-Cell Non-Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Refractory Hodgkin Lymphoma / Refractory Mantle Cell Lymphoma / Refractory T-Cell Non-Hodgkin Lymphoma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2Active Not RecruitingTreatmentB-Cell Malignancies1
1, 2Active Not RecruitingTreatmentBrain and Central Nervous System Tumors / Cancer, Ovarian / Childhood Germ Cell Tumor / Extragonadal Germ Cell Tumor / Liver Cancer / Malignant Lymphomas / Neuroblastomas / Renal Cancers / Sarcomas / Testicular germ cell tumour / Unspecified Childhood Solid Tumor, Protocol Specific1
1, 2Active Not RecruitingTreatmentCarcinoma of Unknown Primary Origin / Carcinoma, Small Cell / Extensive Stage Small Cell Lung Carcinoma / Large Cell Lung Carcinoma / Neuroendocrine Carcinomas / Newly Diagnosed Carcinoma of Unknown Primary Origin / Stage IV Non-Small Cell Lung Cancer / Stage IV Non-Small Cell Lung Cancer AJCC v71
1, 2Active Not RecruitingTreatmentClassical Hodgkin Lymphoma1
1, 2Active Not RecruitingTreatmentDiffuse Large B Cell Lymphoma Refractory / Diffuse Large B Cell Lymphoma Relapsed1
1, 2Active Not RecruitingTreatmentExtensive Stage Small Cell Lung Cancer / Recurrent Small Cell Lung Cancer1
1, 2Active Not RecruitingTreatmentLeukemia, Myeloid, Acute1
1, 2Active Not RecruitingTreatmentLeukemia, Prolymphocytic / Recurrent Adult Hodgkin's Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Non-Hodgkin Lymphoma / Recurrent Small Lymphocytic Lymphoma / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hodgkin Lymphoma / Refractory Non-Hodgkin's lymphoma / Refractory Small Lymphocytic Lymphoma / T-cell chronic lymphocytic leukaemia / T-Cell Prolymphocytic Leukemia1
1, 2Active Not RecruitingTreatmentLeukemias1
1, 2Active Not RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)2
1, 2Active Not RecruitingTreatmentLung Cancers1
1, 2Active Not RecruitingTreatmentMalignant Lymphomas1
1, 2Active Not RecruitingTreatmentPreviously Treated Myelodysplastic Syndromes / Recurrent Adult Acute Myeloid Leukemia1
1, 2Active Not RecruitingTreatmentRecurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Hodgkin's Lymphoma1
1, 2Active Not RecruitingTreatmentRecurrent Childhood Acute Lymphoblastic Leukemia1
1, 2Active Not RecruitingTreatmentRelapsed/Refractory Sarcomas / Tumors, Solid1
1, 2Active Not RecruitingTreatmentStage IV Small Cell Lung Cancer1
1, 2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myelogenous Leukaemia (AML) / Relapsed Leukemia1
1, 2CompletedTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Contiguous Stage II Mantle Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Noncontiguous Stage II Mantle Cell Lymphoma / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Stage I Cutaneous T-cell Non-Hodgkin Lymphoma / Stage I Mantle Cell Lymphoma / Stage I Mycosis Fungoides/Sezary Syndrome / Stage II Cutaneous T-cell Non-Hodgkin Lymphoma / Stage II Mycosis Fungoides/Sezary Syndrome / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Waldenstrom's Macroglobulinemia (WM)1
1, 2CompletedTreatmentAdult T-cell lymphomas/leukaemias1
1, 2CompletedTreatmentCancer, Breast1
1, 2CompletedTreatmentCancer, Ovarian / Extragonadal Germ Cell Tumor / Testicular germ cell tumour2
1, 2CompletedTreatmentChemonaive / Extensive Stage Lung Cancer / Lung Cancer Small Cell Lung Cancer (SCLC)1
1, 2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Myelodysplastic Syndromes / Thrombocytopenias1
1, 2CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Lung Cancers / Radiation Toxicity1
1, 2CompletedTreatmentExtensive-Stage Small Cell Lung Cancer1
1, 2CompletedTreatmentExtensive-Stage Small Cell Lung Cancer / Lung Cancer Small Cell Lung Cancer (SCLC) / Lung Cancers / Tumors, Solid1
1, 2CompletedTreatmentExtensive-Stage Small-Cell Lung Cancer1
1, 2CompletedTreatmentHodgkins Disease (HD) / Malignant Lymphomas1
1, 2CompletedTreatmentLeukemia, Myeloid, Acute1
1, 2CompletedTreatmentLeukemias3
1, 2CompletedTreatmentLeukemias / Malignant Lymphomas1
1, 2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)2
1, 2CompletedTreatmentLung Cancers3
1, 2CompletedTreatmentLymphoma, Hodgkins1
1, 2CompletedTreatmentMalignant Lymphomas3
1, 2CompletedTreatmentMantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL)1
1, 2CompletedTreatmentMultiple Myeloma (MM)1
1, 2CompletedTreatmentRecurrent Adult Diffuse Large Cell Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma1
1, 2Not Yet RecruitingTreatmentAdult Burkitt Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Lymphoma, Large B-Cell, Diffuse (DLBCL) / MYC Gene Mutation / Plasmablastic Lymphoma1
1, 2RecruitingTreatmentALK- Anaplastic Large Cell Lymphoma (ALCL) / ALK- Anaplastic Largecell Lymphoma (ALCL) / Angioimmunoblastic T-cell Lymphoma (AITL) / Peripheral T-Cell Lymphoma (PTCL) / Peripheral T-cell Lymphomas Not Otherwise Specified (PTCL-NOS) / PTCL-NOS1
1, 2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
1, 2RecruitingTreatmentAcute Myelogenous Leukaemia (AML) / Acute Myeloid Leukaemias (AML) / Leukemias1
1, 2RecruitingTreatmentAcute Myeloid Leukaemias (AML)1
1, 2RecruitingTreatmentAdult Anaplastic Oligodendroglioma / Adult Mixed Glioma / Adult Oligodendroglioma / Oligoastrocytoma / Recurrent Adult Brain Neoplasm1
1, 2RecruitingTreatmentAnaplastic Large Cell Lymphoma, ALK-Negative / Anaplastic Large Cell Lymphoma, ALK-Positive / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma, Not Otherwise Specified / Stage II Angioimmunoblastic T-cell Lymphoma / Stage II Enteropathy-Associated T-Cell Lymphoma / Stage III Angioimmunoblastic T-cell Lymphoma / Stage III Enteropathy-Associated T-Cell Lymphoma / Stage IV Angioimmunoblastic T-cell Lymphoma / Stage IV Enteropathy-Associated T-Cell Lymphoma1
1, 2RecruitingTreatmentCD20 Positive / Contiguous Stage II Adult Diffuse Large Cell Lymphoma / Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Diffuse Large B-Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Stage I Adult Diffuse Large Cell Lymphoma / Stage I Diffuse Large B-Cell Lymphoma / Stage II Diffuse Large B-Cell Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Diffuse Large B-Cell Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Diffuse Large B-Cell Lymphoma1
1, 2RecruitingTreatmentCD20 Positive / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Recurrent Diffuse Large B-Cell Lymphoma / Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma / Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma / Transformed Recurrent Non-Hodgkin Lymphoma1
1, 2RecruitingTreatmentDifferentiated Thyroid Cancer (DTC) / Sarcoma, Osteogenic / Solid Malignant Tumors / Tumors1
1, 2RecruitingTreatmentHigh-risk Medulloblastoma1
1, 2RecruitingTreatmentHodgkins Disease (HD)1
1, 2RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Plasmablastic Lymphoma / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Burkitt Lymphoma / Recurrent Follicular Lymphoma / Stage III Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage IV Follicular Lymphoma / Stage IV Mantle Cell Lymphoma1
1, 2RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
1, 2RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
1, 2RecruitingTreatmentRecurrent Adult Hodgkin's Lymphoma / Refractory Hodgkin Lymphoma1
1, 2RecruitingTreatmentRelapsed/Refractory Acute Myeloid Leukemia (AML)1
1, 2RecruitingTreatmentStage IIIA Non-Small Cell Lung Cancer1
1, 2RecruitingTreatmentT Cell Non-Hodgkin's Lymphoma1
1, 2TerminatedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
1, 2TerminatedTreatmentAnaplastic Large Cell Lymphoma / Recurrent Childhood Anaplastic Large Cell Lymphoma1
1, 2TerminatedTreatmentCancer, Ovarian1
1, 2TerminatedTreatmentCarcinoma, Small Cell1
1, 2TerminatedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)2
1, 2TerminatedTreatmentLung Cancers / Non-Small-Cell Lung Carcinoma (NSCLC)1
1, 2TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
1, 2TerminatedTreatmentRelapsed T-Cell Acute Lymphoblastic Leukemia / Relapsed T-Cell Lymphoblastic Lymphoma1
1, 2TerminatedTreatmentSmall Cell Lung Carcinoma2
1, 2Unknown StatusTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Splenic Marginal Zone Lymphoma / Stage III Adult Burkitt Lymphoma / Stage III Adult Diffuse Large Cell Lymphoma / Stage III Adult Diffuse Mixed Cell Lymphoma / Stage III Adult Diffuse Small Cleaved Cell Lymphoma / Stage III Adult Immunoblastic Large Cell Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage III Grade 1 Follicular Lymphoma / Stage III Grade 2 Follicular Lymphoma / Stage III Grade 3 Follicular Lymphoma / Stage III Mantle Cell Lymphoma / Stage III Marginal Zone Lymphoma / Stage III Mycosis Fungoides/Sezary Syndrome / Stage III Small Lymphocytic Lymphoma / Stage IV Adult Burkitt Lymphoma / Stage IV Adult Diffuse Large Cell Lymphoma / Stage IV Adult Diffuse Mixed Cell Lymphoma / Stage IV Adult Diffuse Small Cleaved Cell Lymphoma / Stage IV Adult Immunoblastic Large Cell Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma / Stage IV Grade 1 Follicular Lymphoma / Stage IV Grade 2 Follicular Lymphoma / Stage IV Grade 3 Follicular Lymphoma / Stage IV Mantle Cell Lymphoma / Stage IV Marginal Zone Lymphoma / Stage IV Mycosis Fungoides/Sezary Syndrome / Stage IV Small Lymphocytic Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
1, 2Unknown StatusTreatmentCancer, Ovarian / Fallopian Tube Cancer / Primary Peritoneal Cavity Cancer1
1, 2Unknown StatusTreatmentMalignant Lymphomas1
1, 2WithdrawnTreatmentLarge Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease / Primary Effusion Lymphomas1
1, 2WithdrawnTreatmentLarge-Cell Lymphoma, Diffuse / Lymphoma, Diffuse Large-Cell / Lymphoma, Diffuse Large-Cell B-cell / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2WithdrawnTreatmentLymphoma, Hodgkins / Malignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
1, 2WithdrawnTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
1, 2WithdrawnTreatmentMalignant Lymphomas1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2Active Not RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAcute Myeloid Leukemia With Myelodysplasia-Related Changes / Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11 / Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1 / Adult Acute Myeloid Leukemia With t(9;11)(p22.3;q23.3); MLLT3-KMT2A / Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL / Untreated Adult Acute Myeloid Leukemia1
2Active Not RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult B Acute Lymphoblastic Leukemia / Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Adult L1 Acute Lymphoblastic Leukemia / Adult L2 Acute Lymphoblastic Leukemia / Adult T Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia1
2Active Not RecruitingTreatmentAdult Diffuse Large B-Cell Lymphoma / B-cell Non-Hodgkin's Lymphomas / Follicular Lymphoma (FL) / Mantle Cell Lymphoma (MCL) / Non-Hodgkin's Lymphoma (NHL) / T-Cell Non-Hodgkin Lymphoma1
2Active Not RecruitingTreatmentAdvanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentChildhood Central Nervous System Germ Cell Tumor / Childhood Central Nervous System Germinoma1
2Active Not RecruitingTreatmentChildhood Germ Cell Tumor / Neoplasms, Brain / Tumors, Central Nervous System1
2Active Not RecruitingTreatmentChronic Lymphocytic Leukaemia (CLL) / Lymphoma, Hodgkins / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Lymphoma, Low-Grade / Lymphoma, Mantle-Cell / Small Lymphocytic Lymphoma (SLL) / T-Cell Lymphomas1
2Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Precancerous/Nonmalignant Condition1
2Active Not RecruitingTreatmentDesmoplastic Small Round Cell Tumor (DSRCT) / Ewing Sarcoma of Bone or Soft Tissue / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor1
2Active Not RecruitingTreatmentDiffuse Large Cell Lymphoma / Malignant Lymphomas1
2Active Not RecruitingTreatmentExtensive Stage Small Cell Lung Cancer / Extensive Stage Small Cell Lung Carcinoma / Recurrent Small Cell Lung Cancer / Recurrent Small Cell Lung Carcinoma1
2Active Not RecruitingTreatmentHigh Risk Neuroblastoma1
2Active Not RecruitingTreatmentHodgkins Disease (HD) / Non-Hodgkin's Lymphoma (NHL)1
2Active Not RecruitingTreatmentLeukemias1
2Active Not RecruitingTreatmentLeukemias / Myelodysplastic Syndromes1
2Active Not RecruitingTreatmentLymphoma, B-Cell1
2Active Not RecruitingTreatmentLymphoma, Hodgkins4
2Active Not RecruitingTreatmentMalignant Fibrous Histiocytoma (MFH) of Bone / Sarcoma, Osteogenic1
2Active Not RecruitingTreatmentMalignant Lymphomas10
2Active Not RecruitingTreatmentMalignant Lymphomas / Nonneoplastic Condition1
2Active Not RecruitingTreatmentNasal Type Extranodal NK/T-Cell Lymphoma1
2Active Not RecruitingTreatmentNeoplasms, Brain / Tumors, Central Nervous System1
2Active Not RecruitingTreatmentNeuroblastomas1
2Active Not RecruitingTreatmentNeuroendocrine Carcinoma of the Skin1
2Active Not RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)3
2Active Not RecruitingTreatmentPrimary Mediastinal Large B Cell Lymphoma1
2Active Not RecruitingTreatmentRetinoblastoma1
2Active Not RecruitingTreatmentSarcomas1
2CompletedNot AvailableLeukemias / Non-Hodgkin's Lymphoma (NHL)1
2CompletedDiagnosticMalignant Lymphomas1
2CompletedDiagnosticNeoplasms1
2CompletedPreventionUnresectable Locally Advanced NSCLC1
2CompletedSupportive CareCancer, Breast / Cancer, Ovarian / Drug/Agent Toxicity by Tissue/Organ / Lung Cancers / Malignant Lymphomas / Unspecified Adult Solid Tumor, Protocol Specific1
2CompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Infection NOS / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Precancerous Conditions / Secondary Myelofibrosis / Small Intestine Cancer1
2CompletedSupportive CareDrug/Agent Toxicity by Tissue/Organ / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Oral Complications / Radiation Toxicity1
2CompletedSupportive CareLeukemias / Malignant Lymphomas / Oral Complications1
2CompletedSupportive CareMalignant Lymphomas / Neutropenias1
2CompletedTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma1
2CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
2CompletedTreatmentAcute Lymphoblastic Leukemia, Mature B-Cell / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentAcute Myeloid Leukaemias (AML)1
2CompletedTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndrome1
2CompletedTreatmentAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2CompletedTreatmentAdenocarcinoma of Colon / Adenocarcinoma of Rectum / Metastatic Disease1
2CompletedTreatmentAdult Acute Lymphoblastic Leukemia in Remission1
2CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Recurrent Adult Acute Myeloid Leukemia1
2CompletedTreatmentAdult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Childhood Acute Basophilic Leukemia / Childhood Acute Eosinophilic Leukemia / Childhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia1
2CompletedTreatmentAdult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Childhood Acute Myeloid Leukemia in Remission / Recurrent Adult Acute Myeloid Leukemia / Recurrent Childhood Acute Myeloid Leukemia1
2CompletedTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Multiple Myeloma / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentAdult Rhabdomyosarcoma / Childhood Alveolar Rhabdomyosarcoma / Childhood Embryonal Rhabdomyosarcoma / Metastatic Childhood Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma / Untreated Childhood Rhabdomyosarcoma1
2CompletedTreatmentAlveolar Childhood Rhabdomyosarcoma / Embryonal Childhood Rhabdomyosarcoma / Embryonal-botryoid Childhood Rhabdomyosarcoma / Previously Treated Childhood Rhabdomyosarcoma / Recurrent Childhood Rhabdomyosarcoma1
2CompletedTreatmentAnaplastic Large Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Nodal marginal zone B-cell lymphomas / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Splenic Marginal Zone Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
2CompletedTreatmentB-All / Burkitt's Lymphoma1
2CompletedTreatmentB-cell Adult Acute Lymphoblastic Leukemia / B-cell Childhood Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Lymphoblastic Lymphoma / T-cell Adult Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentBladder Cancers / Brain and Central Nervous System Tumors / Cancer, Ovarian / Carcinoma of Unknown Primary / Extragonadal Germ Cell Tumor / Head and Neck Carcinoma / Lung Cancers / Renal Cancers / Sarcomas / Testicular germ cell tumour / Unspecified Adult Solid Tumor, Protocol Specific1
2CompletedTreatmentBone Marrow Ablation / Leukemias1
2CompletedTreatmentBrain Stem Gliomas1
2CompletedTreatmentBrain and Central Nervous System Tumors6
2CompletedTreatmentBrain and Central Nervous System Tumors / Cancer, Ovarian / Extragonadal Germ Cell Tumor / Teratoma / Testicular germ cell tumour1
2CompletedTreatmentBrain and Central Nervous System Tumors / Extragonadal Germ Cell Tumor / Pediatric Germ Cell Tumor1
2CompletedTreatmentBrain and Central Nervous System Tumors / Head and Neck Carcinoma / Malignant Lymphomas1
2CompletedTreatmentCancer, Breast4
2CompletedTreatmentCancer, Breast / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Testicular germ cell tumour / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentCancer, Ovarian / Childhood Germ Cell Tumor / Drug/Agent Toxicity by Tissue/Organ / Extragonadal Germ Cell Tumor1
2CompletedTreatmentCancer, Ovarian / Extragonadal Germ Cell Tumor1
2CompletedTreatmentCancer, Ovarian / Extragonadal Germ Cell Tumor / Testicular germ cell tumour / Unspecified Adult Solid Tumor, Protocol Specific1
2CompletedTreatmentCancer, Ovarian / Sarcomas / Small Intestine Cancer1
2CompletedTreatmentCentral Nervous System Tumor, Pediatric1
2CompletedTreatmentCentral Nervous System Tumor, Pediatric / Leukemias / Malignant Lymphomas / Neuroblastomas / Sarcomas / Unspecified Childhood Solid Tumor, Protocol Specific1
2CompletedTreatmentChildhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Stage I Childhood Large Cell Lymphoma / Stage I Childhood Small Noncleaved Cell Lymphoma / Stage II Childhood Large Cell Lymphoma / Stage II Childhood Small Noncleaved Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage III Childhood Small Noncleaved Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma / Stage IV Childhood Small Noncleaved Cell Lymphoma / Untreated Childhood Acute Lymphoblastic Leukemia1
2CompletedTreatmentChildhood Renal Cell Carcinoma / Clear Cell Renal Cell Carcinoma / Clear Cell Sarcoma of the Kidney / Papillary Renal Cell Carcinoma / Rhabdoid Tumors of the Kidney (RTK) / Stage I Renal Cell Cancer / Stage I Renal Wilms Tumor / Stage II Renal Cell Cancer / Stage II Renal Wilms Tumor / Stage III Renal Cell Cancer / Stage III Renal Wilms Tumor / Stage IV Renal Cell Cancer / Stage IV Renal Wilms Tumor1
2CompletedTreatmentChronic Lymphocytic Leukaemia (CLL) / Leukemias2
2CompletedTreatmentChronic Myeloproliferative Disorders / Leukemias / Multiple Myeloma and Malignant Plasma Cell Neoplasms / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2CompletedTreatmentDisseminated Sclerosis / Relapsing Remitting Multiple Sclerosis (RRMS)1
2CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Lung Cancers / Radiation Toxicity1
2CompletedTreatmentEwings Sarcoma / Neuroblastomas / Non-rhabdomyosarcoma Soft Tissue Sarcomas1
2CompletedTreatmentExtensive Stage Small Cell Lung Cancer2
2CompletedTreatmentExtensive Stage Small Cell Lung Cancer / Recurrent Small Cell Lung Cancer1
2CompletedTreatmentExtensive Stage Small Cell Lung Carcinoma1
2CompletedTreatmentExtensive-Stage Small Cell Lung Cancer1
2CompletedTreatmentExtragonadal Germ Cell Tumor / Teratoma / Testicular germ cell tumour2
2CompletedTreatmentGerm Cell Tumors / Testicular Neoplasms1
2CompletedTreatmentGlioblastomas / Gliosarcoma2
2CompletedTreatmentGraft Versus Host Disease (GVHD) / Malignant Lymphomas1
2CompletedTreatmentHodgkins Disease (HD) / Lymphoma, Hodgkin Disease / Lymphoma, Hodgkins / Malignant Lymphomas2
2CompletedTreatmentHodgkins Disease (HD) / Pediatric1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lymphoma, AIDS Related1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Non-Hodgkin's Lymphoma (NHL)1
2CompletedTreatmentLeptomeningeal Metastasis / Metastatic Brain Tumors / Neoplasms, Breast1
2CompletedTreatmentLeukemias19
2CompletedTreatmentLeukemias / Malignant Lymphomas7
2CompletedTreatmentLeukemias / Malignant Lymphomas / Multiple Myleoma / Myelodysplastic Syndrome / Myeloproliferative Disorders1
2CompletedTreatmentLeukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases1
2CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Neutropenias1
2CompletedTreatmentLeukemias / Neutropenias / Thrombocytopenias1
2CompletedTreatmentLimited Stage Small Cell Lung Cancer1
2CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)2
2CompletedTreatmentLung Cancers12
2CompletedTreatmentLymphohistiocytosis, Hemophagocytic1
2CompletedTreatmentLymphoma, B-Cell1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2CompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / POOR PROGNOSIS1
2CompletedTreatmentLymphoma, Large Cell, Diffuse1
2CompletedTreatmentMalignant Lymphomas51
2CompletedTreatmentMalignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm2
2CompletedTreatmentMalignant Lymphomas / Neurotoxicity1
2CompletedTreatmentMalignant Neoplasm of Pancreas1
2CompletedTreatmentMetastatic Breast Cancer (MBC)1
2CompletedTreatmentMetastatic Osteosarcoma1
2CompletedTreatmentMetastatic, Cerebral Primitive Neuroectodermal Tumors1
2CompletedTreatmentMultiple Myeloma (MM)3
2CompletedTreatmentMultiple Myeloma and Plasma Cell Neoplasm2
2CompletedTreatmentNeoplasms, Brain / Tumors, Central Nervous System1
2CompletedTreatmentNeuroblastomas11
2CompletedTreatmentNeuroendocrine Carcinomas1
2CompletedTreatmentNeurofibromatosis Type 1 / Sarcomas1
2CompletedTreatmentNeutropenias / Sarcomas1
2CompletedTreatmentNon-Hodgkin's Lymphoma (NHL)2
2CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)3
2CompletedTreatmentProstate Cancer6
2CompletedTreatmentRenal Cancers / Sarcomas1
2CompletedTreatmentRetinoblastoma2
2CompletedTreatmentSarcoma, Osteogenic1
2CompletedTreatmentSarcomas3
2CompletedTreatmentSoft Tissue Sarcoma (STS)1
2CompletedTreatmentTesticular Neoplasms1
2CompletedTreatmentUntreated Childhood Medulloblastoma1
2CompletedTreatmentAdvanced thymic carcinoma1
2Enrolling by InvitationTreatmentAcute,Leukemia, Lymphoid1
2Enrolling by InvitationTreatmentMultiple Myeloma (MM)1
2Not Yet RecruitingTreatmentAML1
2Not Yet RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Burkitt Leukemia/Lymphoma / Hematopoietic/Lymphoid Cancer / Lymphoma, Lymphoblastic1
2Not Yet RecruitingTreatmentAggressive Non-Hodgkin Lymphoma1
2Not Yet RecruitingTreatmentB Acute Lymphoblastic Leukemia / B Lymphoblastic Lymphoma / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent B Lymphoblastic Lymphoma / Recurrent T Lymphoblastic Leukemia/Lymphoma / Refractory B Lymphoblastic Lymphoma / Refractory T Lymphoblastic Lymphoma / T Acute Lymphoblastic Leukemia / T Lymphoblastic Lymphoma1
2Not Yet RecruitingTreatmentB-cell Non-Hodgkin's Lymphomas1
2Not Yet RecruitingTreatmentLung1
2Not Yet RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)3
2Not Yet RecruitingTreatmentMalignant Neoplasm of Stomach / Stomach Neoplasms1
2Not Yet RecruitingTreatmentMantle Cell Lymphoma (MCL)1
2Not Yet RecruitingTreatmentMultiple Myeloma (MM)1
2Not Yet RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2Not Yet RecruitingTreatmentPulmonary Large Cell Neuroendocrine Carcinoma1
2Not Yet RecruitingTreatmentSmall Cell Lung Cancer Extensive Stage1
2RecruitingNot AvailableSeminoma1
2RecruitingBasic ScienceRecurrent Adult Acute Myeloid Leukemia / Secondary Acute Myeloid Leukemia / Untreated Adult Acute Myeloid Leukemia1
2RecruitingPreventionExtensive-Stage Small Cell Lung Cancer / Lung Cancers1
2RecruitingPreventionMultiple Myeloma (MM)1
2RecruitingSupportive CareGliomas1
2RecruitingTreatmentAIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Diffuse Mixed Cell Lymphoma / AIDS-Related Diffuse Small Cleaved Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-Related Lymphoblastic Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma / Stage III AIDS-related Lymphoma / Stage IV AIDS-related Lymphoma1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML)1
2RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Leukemia, B-Cell / Leukemia, T-Cell / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentAcute Lymphocytic Leukemia (ALL) / Adult Lymphoblastic Lymphoma1
2RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Myelodysplastic Syndromes1
2RecruitingTreatmentAdult Acute Lymphoblastic Leukemia / Adult Lymphoblastic Lymphoma / CD20 Positive / Philadelphia Chromosome Positive1
2RecruitingTreatmentAdult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia1
2RecruitingTreatmentAdult T-Cell Leukemia/Lymphoma / Anaplastic Large Cell Lymphoma, ALK-Negative / Anaplastic Large Cell Lymphoma, ALK-Positive / Angioimmunoblastic T-Cell Lymphoma / CD30-Positive Neoplastic Cells Present / Enteropathy-Associated T-Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma / Peripheral T-Cell Lymphoma, Not Otherwise Specified / Stage III Anaplastic Large Cell Lymphoma / Stage IV Anaplastic Large Cell Lymphoma1
2RecruitingTreatmentAll1
2RecruitingTreatmentAtypical Teratoid Rhabdoid Tumors (ATRT) / Malignant Rhabdoid Tumors (MRT)1
2RecruitingTreatmentAutoimmune Diseases / Autoimmune Disorders1
2RecruitingTreatmentB-Cell Prolymphocytic Leukemia / Hypodiploidy / Leukemia, Plasma Cell / Loss of Chromosome 17p / Progression of Multiple Myeloma or Plasma Cell Leukemia / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Non-Hodgkin Lymphoma / Recurrent Childhood Hodgkin Lymphoma / Recurrent Childhood Non-Hodgkin Lymphoma / Recurrent Chronic Lymphocytic Leukemia / Recurrent Plasma Cell Myeloma / Recurrent Small Lymphocytic Lymphoma / Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Non-Hodgkin's lymphoma / Refractory Plasma Cell Myeloma / Refractory Small Lymphocytic Lymphoma / T(14;16) / T(4;14) / T-Cell Prolymphocytic Leukemia / Waldenstrom's Macroglobulinemia (WM)1
2RecruitingTreatmentBurkitt's Lymphoma / CD20+ Lymphoblastic Lymphoma / Follicular Lymphoma, Grade III / Lymphoma, Large B-Cell, Diffuse (DLBCL) / Non-Hodgkin's Lymphoma (NHL) / Primary Mediastinal B-Cell Lymphoma1
2RecruitingTreatmentCD (Cluster of Differentiation) 30-Positive Neoplastic Cells Present / Recurrent Hodgkin Lymphoma / Refractory Hodgkin Lymphoma1
2RecruitingTreatmentCancer, Breast / Metastatic Brain Tumors1
2RecruitingTreatmentCancer, Ovarian2
2RecruitingTreatmentCancer, Ovarian / Childhood Germ Cell Tumor / Teratoma1
2RecruitingTreatmentCancers1
2RecruitingTreatmentChildren / Retinal Neoplasms / Retinoblastoma1
2RecruitingTreatmentColorectal Large Cell Neuroendocrine Carcinoma / Esophageal Large Cell Neuroendocrine Carcinoma / Gallbladder Large Cell Neuroendocrine Carcinoma / Gastric Large Cell Neuroendocrine Carcinoma / Pancreatic Large Cell Neuroendocrine Carcinoma / Small Intestinal Large Cell Neuroendocrine Carcinoma1
2RecruitingTreatmentDiffuse Large Cell Lymphoma Relapsed/Refractory1
2RecruitingTreatmentEwing's Sarcoma (ES)1
2RecruitingTreatmentExtramedullary Plasmacytoma / Isolated Plasmacytoma of Bone / Light Chain Deposition Disease / Primary Systemic Amyloidosis / Stage I Multiple Myeloma / Stage II Multiple Myeloma / Stage III Multiple Myeloma1
2RecruitingTreatmentExtranodal NK-T-CELL LYMPHOMA / NK/T Cell Lymphoma1
2RecruitingTreatmentFollicular Lymphoma (FL)1
2RecruitingTreatmentFollicular Lymphoma, Grade 3b / Lymphoma, B-Cell / Lymphoma, Follicular, Grade 3b / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
2RecruitingTreatmentGerm Cell Tumors2
2RecruitingTreatmentHHV-8 / HIV Disease / Lymphoproliferative Disorders / Malignancies1
2RecruitingTreatmentHodgkins Disease (HD)1
2RecruitingTreatmentIntracranial Germinoma1
2RecruitingTreatmentIntracranial Non-germinomatous Germ Cell Tumor1
2RecruitingTreatmentLeukaemia, Lymphoblastic1
2RecruitingTreatmentLeukemias2
2RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)2
2RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC) / Small Cell Lung Cancer Extensive Stage / Small Cell Lung Cancer Limited Stage1
2RecruitingTreatmentLymphocyte-Rich Classical Hodgkin Lymphoma / Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma / Recurrent Mixed Cellularity Classical Hodgkin Lymphoma / Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma / Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma / Refractory Mixed Cellularity Classical Hodgkin Lymphoma / Refractory Nodular Sclerosis Classical Hodgkin Lymphoma1
2RecruitingTreatmentLymphoma, Extranodal NK-T-Cell1
2RecruitingTreatmentLymphoma, Hodgkins1
2RecruitingTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)2
2RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Refractory Diffuse Large B-cell Lymphoma (DLBCL) / Relapsed Diffuse Large B-cell Lymphoma (DLBCL)1
2RecruitingTreatmentLymphoma, Mantle-Cell / Malignant Lymphomas1
2RecruitingTreatmentMalignant Lymphomas3
2RecruitingTreatmentMedulloblastomas2
2RecruitingTreatmentNeuroblastoma Recurrent1
2RecruitingTreatmentNeuroblastomas2
2RecruitingTreatmentNewly Diagnosed Ewing Sarcoma1
2RecruitingTreatmentNewly Diagnosed High Risk Neuroblastoma1
2RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
2RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2RecruitingTreatmentOvarian Granulosa Cell Tumor / Ovarian Gynandroblastoma / Ovarian Sertoli-Leydig Cell Tumors / Ovarian Sex Cord Tumor With Annular Tubules / Ovarian Sex Cord-Stromal Tumor / Ovarian Sex Cord-Stromal Tumor of Mixed or Unclassified Cell Types / Ovarian Steroid Cell Tumor1
2RecruitingTreatmentPediatric Acute Myeloid Leukemia1
2RecruitingTreatmentPeripheral T-Cell Lymphoma (PTCL)1
2RecruitingTreatmentPlasma Cell Myeloma1
2RecruitingTreatmentRecurrent B-Cell Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood B-Lymphoblastic Lymphoma1
2RecruitingTreatmentRecurrent Non-small Cell Lung Cancer / Stage IIA Non-small Cell Lung Cancer / Stage IIB Non-small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
2RecruitingTreatmentRefractory Pediatric AML / Refractory Pediatric Solid Tumors / Relapsed Pediatric AML / Relapsed Pediatric Solid Tumors1
2RecruitingTreatmentRetinoblastoma2
2RecruitingTreatmentRhabdomyosarcomas1
2RecruitingTreatmentSinonasal Tumors1
2RecruitingTreatmentStage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
2RecruitingTreatmentStage III Non-Small Cell Lung Cancer AJCC v7 / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer AJCC v7 / Stage IIIB Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer AJCC v71
2RecruitingTreatmentTesticular Cancer1
2RecruitingTreatmentTreatment Refusal1
2RecruitingTreatmentUnresectable Localized Soft Tissue Sarcoma1
2RecruitingTreatmentUnresectable Sinonasal Tumors1
2SuspendedTreatmentAnaplastic Large Cell Lymphoma, ALK-Positive / CD30-Positive Neoplastic Cells Present / Stage II Childhood Anaplastic Large Cell Lymphoma / Stage III Childhood Anaplastic Large Cell Lymphoma / Stage IV Childhood Anaplastic Large Cell Lymphoma1
2SuspendedTreatmentSmall Cell Lung Carcinoma1
2TerminatedDiagnosticMalignant Lymphomas1
2TerminatedTreatmentAcute Lymphocytic Leukemia (ALL) / Acute Myelogenous Leukaemia (AML) / Aplastic Anaemia (AA) / Chronic Lymphocytic Leukaemia (CLL) / Chronic Myelogenous Leukemia (CML) / Hodgkins Disease (HD) / Multiple Myeloma (MM) / Myelodysplastic Syndrome / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentAtypical Burkitt Lymphoma / Burkitt's Lymphoma / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / L3 Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma1
2TerminatedTreatmentBrain and Central Nervous System Tumors / Drug/Agent Toxicity by Tissue/Organ / Malignant Lymphomas / Thrombocytopenias1
2TerminatedTreatmentCancer, Breast2
2TerminatedTreatmentCancer, Ovarian / Cervical Cancers1
2TerminatedTreatmentCancer, Ovarian / Childhood Germ Cell Tumor / Extragonadal Germ Cell Tumor / Testicular germ cell tumour1
2TerminatedTreatmentCancers / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Unusual Cancers of Childhood1
2TerminatedTreatmentHER-2 Positive Metastatic Breast Cancer1
2TerminatedTreatmentHematologic Diseases1
2TerminatedTreatmentHepatocellular,Carcinoma1
2TerminatedTreatmentHodgkins Disease (HD)1
2TerminatedTreatmentLung Cancers3
2TerminatedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Non-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentLymphoma, Lymphoblastic1
2TerminatedTreatmentMalignant Lymphomas1
2TerminatedTreatmentMedulloblastomas / Neoplasms, Brain / Primitive Neuroectodermal Tumor / Tumors, Central Nervous System1
2TerminatedTreatmentMultiple Myeloma (MM)2
2TerminatedTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2TerminatedTreatmentNeoplasms, Oropharyngeal1
2TerminatedTreatmentNeuroblastomas1
2TerminatedTreatmentNon-Hodgkin's Lymphoma (NHL)1
2TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
2TerminatedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC) / Stage IIIA (N2)1
2TerminatedTreatmentRecurrent or Refractory Pediatric Ependymoma1
2TerminatedTreatmentRelapsed Acute Myelogenous Leukemia1
2TerminatedTreatmentSarcomas2
2TerminatedTreatmentSmall Cell Lung Carcinoma1
2TerminatedTreatmentT-Cell Non-Hodgkin Lymphoma1
2Unknown StatusDiagnosticLung Cancers1
2Unknown StatusSupportive CareChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
2Unknown StatusSupportive CareDrug/Agent Toxicity by Tissue/Organ / Lung Cancers / Radiation Toxicity1
2Unknown StatusTreatmentAcute Myeloid Leukaemias (AML)1
2Unknown StatusTreatmentAnaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Hepatosplenic T-Cell Lymphoma / Peripheral T-Cell Lymphoma (PTCL)1
2Unknown StatusTreatmentBrain and Central Nervous System Tumors3
2Unknown StatusTreatmentBrain and Central Nervous System Tumors / Extragonadal Germ Cell Tumor / Testicular germ cell tumour1
2Unknown StatusTreatmentCancer, Breast2
2Unknown StatusTreatmentExtranodal NK/T-cell Lymphoma, Nasal Type1
2Unknown StatusTreatmentHIV-associated Hodgkin Lymphoma1
2Unknown StatusTreatmentLeukemias4
2Unknown StatusTreatmentLung Cancers3
2Unknown StatusTreatmentLymphoma, Mantle-Cell1
2Unknown StatusTreatmentMalignant Lymphomas15
2Unknown StatusTreatmentMalignant Lymphomas / Small Intestine Cancer1
2Unknown StatusTreatmentMedulloblastomas / Neoplasms, Brain / Neuroectodermal Tumors, Primitive1
2Unknown StatusTreatmentMultiple Myeloma and Plasma Cell Neoplasm1
2Unknown StatusTreatmentNHL With Hemophagocytic Lymphohistiocytosis1
2Unknown StatusTreatmentNeoplasms, Brain1
2Unknown StatusTreatmentNeuroblastomas1
2Unknown StatusTreatmentNon Hodgkin Lymphoma (NHL)1
2Unknown StatusTreatmentNon-Hodgkin's Lymphoma (NHL)3
2Unknown StatusTreatmentProstate Cancer1
2Unknown StatusTreatmentRenal Cancers1
2Unknown StatusTreatmentRetinal Neoplasms / Retinoblastoma1
2WithdrawnTreatmentAcute Lymphoblastic Leukaemias (ALL) / Acute Myeloid Leukaemias (AML)1
2WithdrawnTreatmentAdult Non-Hodgkin's Lymphoma / Anaplastic Large Cell Lymphoma / Lymphoma, AIDS Related1
2WithdrawnTreatmentBrain and Central Nervous System Tumors / Neuroblastomas / Retinoblastoma / Sarcomas1
2WithdrawnTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
2WithdrawnTreatmentLung Cancers1
2WithdrawnTreatmentMalignant Lymphomas3
2WithdrawnTreatmentMultiple Myeloma (MM) / Plasma Cell Myeloma1
2WithdrawnTreatmentStage III Non-Small Cell Lung Cancer1
2, 3Active Not RecruitingTreatmentChildhood B Acute Lymphoblastic Leukemia / Childhood Burkitt Leukemia / Childhood Diffuse Large Cell Lymphoma / Mediastinal (Thymic) Large B-Cell Lymphoma / Stage III Childhood Large Cell Lymphoma / Stage IV Childhood Large Cell Lymphoma1
2, 3Active Not RecruitingTreatmentChronic Myeloproliferative Disorders / Leukemias / Malignant Lymphomas / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Nonmalignant Neoplasm / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific1
2, 3Active Not RecruitingTreatmentEpendymomas / Medulloblastomas / Recurrent Brain Tumors / Supratentorial PNETs1
2, 3Active Not RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
2, 3CompletedTreatmentAcute Myeloid Leukaemias (AML)1
2, 3CompletedTreatmentAdult B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34;q11.2); BCR-ABL1 / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
2, 3CompletedTreatmentLeukaemia, Acute1
2, 3CompletedTreatmentMalignant Lymphomas1
2, 3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
2, 3RecruitingTreatmentChildhood Ependymoma1
2, 3RecruitingTreatmentLeukemias2
2, 3RecruitingTreatmentLymphoma, Lymphoblastic1
2, 3RecruitingTreatmentMature B-cell Non-Hodgkin Lymphoma1
2, 3TerminatedTreatmentMalignant Lymphomas1
2, 3TerminatedTreatmentNeuroblastomas1
2, 3Unknown StatusTreatmentDe Novo Akute Myeloid Leukemia (AML) / Refractory Anemia With Excess of Blasts in Transformation / Secondary Acute Myeloid Leukemia (AML)1
2, 3Unknown StatusTreatmentExtragonadal Germ Cell Tumor / Teratoma / Testicular germ cell tumour1
3Active Not RecruitingTreatmentAcute Myeloid Leukaemias (AML)2
3Active Not RecruitingTreatmentAcute Myeloid Leukaemias (AML) / Granulocytic Sarcoma / Leukaemia cutis / Myeloid Neoplasm / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Myeloid Neoplasm1
3Active Not RecruitingTreatmentAcute Undifferentiated Leukemia (AUL) / T-cell Childhood Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentAdult Renal Wilms Tumor / Beckwith-Wiedemann Syndrome / Childhood Renal Wilms Tumor / Diffuse Hyperplastic Perilobar Nephroblastomatosis / Hemihypertrophy / Stage I Renal Wilms Tumor / Stage II Renal Wilms Tumor / Stage III Renal Wilms Tumor / Stage IV Renal Wilms Tumor / Stage V Renal Wilms Tumor1
3Active Not RecruitingTreatmentAdult Supratentorial Primitive Neuroectodermal Tumor (PNET) / Childhood Supratentorial Primitive Neuroectodermal Tumor / Ewing Sarcoma of Bone / Extraosseous Ewing Sarcoma / Extraosseous Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Peripheral Primitive Neuroectodermal Tumor of the Kidney / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
3Active Not RecruitingTreatmentB-cell Childhood Acute Lymphoblastic Leukemia / Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia / L1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia1
3Active Not RecruitingTreatmentChildhood Acute Basophilic Leukemia / Childhood Acute Eosinophilic Leukemia / Childhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Secondary Acute Myeloid Leukemia / Secondary Myelodysplastic Syndromes / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3Active Not RecruitingTreatmentChildhood Atypical Teratoid/Rhabdoid Tumor1
3Active Not RecruitingTreatmentChildhood Embryonal Tumor / Childhood Extracranial Germ Cell Tumor / Childhood Extragonadal Germ Cell Tumor / Childhood Malignant Ovarian Germ Cell Tumor / Childhood Malignant Testicular Germ Cell Tumor / Childhood Teratoma / Ovarian Embryonal Carcinoma / Ovarian Yolk Sac Tumor / Stage II Malignant Testicular Germ Cell Tumor / Stage IIA Ovarian Germ Cell Tumor / Stage IIB Ovarian Germ Cell Tumor / Stage IIC Ovarian Germ Cell Tumor / Stage III Malignant Testicular Germ Cell Tumor / Stage IIIA Ovarian Germ Cell Tumor / Stage IIIB Ovarian Germ Cell Tumor / Stage IIIC Ovarian Germ Cell Tumor / Testicular Choriocarcinoma and Yolk Sac Tumor / Testicular Embryonal Carcinoma1
3Active Not RecruitingTreatmentChildhood Favorable Prognosis Hodgkin Lymphoma / Childhood Lymphocyte Depletion Hodgkin Lymphoma / Childhood Mixed Cellularity Hodgkin Lymphoma / Childhood Nodular Sclerosis Hodgkin Lymphoma / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma1
3Active Not RecruitingTreatmentChildhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
3Active Not RecruitingTreatmentChoroid Plexus Tumors1
3Active Not RecruitingTreatmentDrug/Agent Toxicity by Tissue/Organ / Leukemias1
3Active Not RecruitingTreatmentExtraocular Retinoblastoma1
3Active Not RecruitingTreatmentInfection, Human Immunodeficiency Virus I / Kaposi s Sarcoma (KS)1
3Active Not RecruitingTreatmentLarge B Cell Lymphoma1
3Active Not RecruitingTreatmentLeukemias2
3Active Not RecruitingTreatmentLocalized Osteosarcoma / Metastatic Osteosarcoma1
3Active Not RecruitingTreatmentLocalized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Recurrent Neuroblastoma / Regional Neuroblastoma / Stage 4 Neuroblastoma / Stage 4S Neuroblastoma1
3Active Not RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3Active Not RecruitingTreatmentLymphoblastic Leukemia, Acute1
3Active Not RecruitingTreatmentLymphoblastic Leukemia, Acute, Childhood2
3Active Not RecruitingTreatmentLymphohistiocytosis, Hemophagocytic1
3Active Not RecruitingTreatmentLymphoma, Hodgkins1
3Active Not RecruitingTreatmentMalignant Lymphomas3
3Active Not RecruitingTreatmentMultiple Myeloma (MM)1
3Active Not RecruitingTreatmentNeoplasms, Brain / Tumors, Central Nervous System1
3Active Not RecruitingTreatmentRetinal Neoplasms / Retinoblastoma1
3Active Not RecruitingTreatmentSarcomas1
3Active Not RecruitingTreatmentSmall Cell Lung Carcinoma1
3Active Not RecruitingTreatmentStage I Adrenocortical Carcinoma / Stage II Adrenocortical Carcinoma / Stage III Adrenocortical Carcinoma / Stage IV Adrenocortical Carcinoma1
3Active Not RecruitingTreatmentStage III Wilms Tumor With Loss of Heterozygosity (LOH) for 1p and 16q / Stage IV Wilms Tumor1
3CompletedSupportive CareCancers / Leukemias / Malignant Lymphomas1
3CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3CompletedTreatmentAcute Myeloid Leukaemias (AML)3
3CompletedTreatmentAdenocarcinoma of the Lung / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
3CompletedTreatmentAdult Acute Basophilic Leukemia / Adult Acute Eosinophilic Leukemia / Adult Acute Erythroid Leukemia (M6) / Adult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Childhood Acute Basophilic Leukemia / Childhood Acute Eosinophilic Leukemia / Childhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Minimally Differentiated Myeloid Leukemia (M0) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Myelodysplastic Syndromes / De Novo Myelodysplastic Syndromes / Untreated Adult Acute Myeloid Leukemia / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3CompletedTreatmentAdult Acute Megakaryoblastic Leukemia (M7) / Adult Acute Minimally Differentiated Myeloid Leukemia (M0) / Adult Acute Monoblastic Leukemia (M5a) / Adult Acute Monocytic Leukemia (M5b) / Adult Acute Myeloblastic Leukemia With Maturation (M2) / Adult Acute Myeloblastic Leukemia Without Maturation (M1) / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Acute Myelomonocytic Leukemia (M4) / Adult Erythroleukemia (M6a) / Adult Pure Erythroid Leukemia (M6b) / Untreated Adult Acute Myeloid Leukemia1
3CompletedTreatmentBrain and Central Nervous System Tumors2
3CompletedTreatmentCancer, Breast1
3CompletedTreatmentCarcinoma, Adrenal Cortical1
3CompletedTreatmentCardiac Toxicity / Malignant Lymphomas2
3CompletedTreatmentCardiac Toxicity / Sarcomas1
3CompletedTreatmentChildhood Acute Erythroleukemia (M6) / Childhood Acute Megakaryocytic Leukemia (M7) / Childhood Acute Monoblastic Leukemia (M5a) / Childhood Acute Monocytic Leukemia (M5b) / Childhood Acute Myeloblastic Leukemia With Maturation (M2) / Childhood Acute Myeloblastic Leukemia Without Maturation (M1) / Childhood Acute Myelomonocytic Leukemia (M4) / Childhood Myelodysplastic Syndromes / Chronic Myelomonocytic Leukemia / De Novo Myelodysplastic Syndromes / Refractory Anemia / Refractory Anemia With Excess Blasts / Refractory Anemia With Excess Blasts in Transformation / Refractory Anemia With Ringed Sideroblasts / Secondary Myelodysplastic Syndromes / Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies1
3CompletedTreatmentChildhood Acute Lymphoblastic Leukemia in Remission / Recurrent Childhood Acute Lymphoblastic Leukemia1
3CompletedTreatmentChildhood Germ Cell Tumor / Extragonadal Germ Cell Tumor / Testicular germ cell tumour1
3CompletedTreatmentChildhood Lymphocyte-Depleted Classical Hodgkin Lymphoma / Childhood Mixed Cellularity Classical Hodgkin Lymphoma / Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma / Childhood Nodular Sclerosis Classical Hodgkin Lymphoma / Malignant Lymphomas / Stage I Childhood Hodgkin Lymphoma / Stage II Childhood Hodgkin Lymphoma / Stage III Childhood Hodgkin Lymphoma / Stage IV Childhood Hodgkin Lymphoma1
3CompletedTreatmentChildhood Malignant Fibrous Histiocytoma of Bone / Sarcomas1
3CompletedTreatmentDrug/Agent Toxicity by Tissue/Organ / Testicular germ cell tumour1
3CompletedTreatmentIntraocular Retinoblastoma2
3CompletedTreatmentLeukemia, Myelocytic, Acute1
3CompletedTreatmentLeukemias7
3CompletedTreatmentLeukemias / Malignant Lymphomas3
3CompletedTreatmentLeukemias / Myelodysplastic Syndromes2
3CompletedTreatmentLeukemias / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms2
3CompletedTreatmentLeukemias / Neutropenias1
3CompletedTreatmentLocalised High Grade Osteosarcoma of the Limbs / Sarcoma, Osteogenic1
3CompletedTreatmentLung Cancer Small Cell Lung Cancer (SCLC)5
3CompletedTreatmentLung Cancers9
3CompletedTreatmentLymphoma, Hodgkins3
3CompletedTreatmentLymphoma, Large-Cell, Diffuse1
3CompletedTreatmentMalignant Lymphomas9
3CompletedTreatmentMediastinal Cancer / Metastatic Cancers / Testicular germ cell tumour1
3CompletedTreatmentMultiple Myeloma (MM)2
3CompletedTreatmentNeoplasms, Brain / Tumors, Central Nervous System1
3CompletedTreatmentNeuroblastomas8
3CompletedTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)2
3CompletedTreatmentProstate Cancer1
3CompletedTreatmentRecurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma1
3CompletedTreatmentRenal Cancers2
3CompletedTreatmentSarcomas2
3CompletedTreatmentSmall Cell Lung Carcinoma1
3CompletedTreatmentSmall Cell Lung Carcinoma, Extensive Disease1
3CompletedTreatmentUnknown Primary Neoplasms1
3CompletedTreatmentUntreated Childhood Medulloblastoma / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor2
3Enrolling by InvitationTreatmentCancer, Ovarian / Neoplasms, Ovarian / Ovarian Germ Cell Cancer1
3Enrolling by InvitationTreatmentCancer, Ovarian / Neoplasms, Ovarian / Ovarian Sex Cord Stromal Tumor1
3Not Yet RecruitingTreatmentAcute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation1
3Not Yet RecruitingTreatmentChildhood Ganglioneuroblastoma / Childhood Neuroblastoma / NMYC Gene Amplification / Recurrent Neuroblastoma1
3Not Yet RecruitingTreatmentGestational Trophoblastic Neoplasms1
3Not Yet RecruitingTreatmentHepatoblastomas / Hepatocellular,Carcinoma1
3Not Yet RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
3RecruitingTreatmentActivated B-Cell-Like Diffuse Large B-Cell Lymphoma / B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma / Diffuse Large B-Cell Lymphoma, Not Otherwise Specified / Recurrent Diffuse Large B-Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult B Acute Lymphoblastic Leukemia / B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative / BCR/ABL1 Fusion Protein Negative / Untreated Adult Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Adult T Acute Lymphoblastic Leukemia / Childhood T Acute Lymphoblastic Leukemia / Stage II Childhood Lymphoblastic Lymphoma / Stage II Contiguous Adult Lymphoblastic Lymphoma / Stage II Non-Contiguous Adult Lymphoblastic Lymphoma / Stage III Adult Lymphoblastic Lymphoma / Stage III Childhood Lymphoblastic Lymphoma / Stage IV Adult Lymphoblastic Lymphoma / Stage IV Childhood Lymphoblastic Lymphoma / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 / BCR-ABL1 Fusion Protein Expression / Minimal Residual Disease / Philadelphia Chromosome Positive / T Acute Lymphoblastic Leukemia / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL) / Lymphoma, Lymphoblastic1
3RecruitingTreatmentAcute Lymphoblastic Leukemia, Pediatric1
3RecruitingTreatmentAdult Germ Cell Tumor / Childhood Extracranial Germ Cell Tumor / Childhood Germ Cell Tumor / Extragonadal Embryonal Carcinoma / Grade 2 Immature Ovarian Teratoma / Grade 3 Immature Ovarian Teratoma / Malignant Germ Cell Tumor / Stage I Ovarian Choriocarcinoma / Stage I Ovarian Embryonal Carcinoma / Stage I Ovarian Teratoma / Stage I Ovarian Yolk Sac Tumor / Stage I Testicular Choriocarcinoma / Stage I Testicular Embryonal Carcinoma / Stage I Testicular Yolk Sac Tumor / Stage II Ovarian Choriocarcinoma / Stage II Ovarian Embryonal Carcinoma / Stage II Ovarian Yolk Sac Tumor / Stage II Testicular Choriocarcinoma / Stage II Testicular Embryonal Carcinoma / Stage II Testicular Yolk Sac Tumor / Stage III Ovarian Choriocarcinoma / Stage III Ovarian Embryonal Carcinoma / Stage III Ovarian Yolk Sac Tumor / Stage III Testicular Choriocarcinoma / Stage III Testicular Embryonal Carcinoma / Stage III Testicular Yolk Sac Tumor / Stage IV Ovarian Choriocarcinoma / Stage IV Ovarian Embryonal Carcinoma / Stage IV Ovarian Yolk Sac Tumor / Testicular Mixed Choriocarcinoma and Embryonal Carcinoma / Testicular Mixed Choriocarcinoma and Teratoma / Testicular Mixed Choriocarcinoma and Yolk Sac Tumor1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentB Acute Lymphoblastic Leukemia / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia1
3RecruitingTreatmentChildhood Acute Myeloid Leukemia / Childhood Myelodysplastic Syndrome / Cytopenias / Down Syndrome (DS) / Myeloid Leukemia Associated With Down Syndrome / Myeloproliferative Neoplasms1
3RecruitingTreatmentChildhood Hodgkin Lymphoma / Classical Hodgkin Lymphoma / Stage IIB Hodgkin Lymphoma / Stage IIIB Hodgkin Lymphoma / Stage IV Hodgkin Lymphoma / Stage IVA Hodgkin Lymphoma / Stage IVB Hodgkin Lymphoma1
3RecruitingTreatmentChildhood Infratentorial Ependymoma / Childhood Supratentorial Ependymoma / Newly Diagnosed Childhood Ependymoma1
3RecruitingTreatmentChildhood Teratoma / Choriocarcinoma / Extragonadal Seminoma / Germ Cell Tumors / Germinoma / Malignant Germ Cell Neoplasm / Mixed Germ Cell Tumor / Non-seminomatous Germ Cell Tumors / Seminoma / Teratoma / Yolk Sac Tumor1
3RecruitingTreatmentClassical Hodgkin Lymphoma1
3RecruitingTreatmentEwing's Sarcoma (ES)1
3RecruitingTreatmentExtranodal NK-T-Cell Lymphoma, Nasal Type1
3RecruitingTreatmentExtranodal NK/T-cell Lymphoma, Nasal Type1
3RecruitingTreatmentGanglioneuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Recurrent Neuroblastoma / Regional Neuroblastoma / Stage 4 Neuroblastoma1
3RecruitingTreatmentGerm Cell Tumors1
3RecruitingTreatmentInfection, Human Immunodeficiency Virus I1
3RecruitingTreatmentLeukemia, Acute Myeloid (AML)1
3RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)2
3RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC) / Small Cell Lung Carcinoma1
3RecruitingTreatmentLung Cancers1
3RecruitingTreatmentLymphohistiocytosis, Hemophagocytic2
3RecruitingTreatmentLymphoma, Extranodal NK-T-Cell1
3RecruitingTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL)1
3RecruitingTreatmentMalignant Neoplasm of Stomach / Stomach Neoplasms1
3RecruitingTreatmentMature B-cell Non-Hodgkin Lymphoma1
3RecruitingTreatmentMetastatic Ewing Sarcoma / Metastatic Malignant Neoplasm in the Bone / Metastatic Malignant Neoplasm in the Bone Marrow / Metastatic Malignant Neoplasm in the Lung / Metastatic Peripheral Primitive Neuroectodermal Tumor of Bone / Peripheral Primitive Neuroectodermal Tumor of Soft Tissues1
3RecruitingTreatmentMultiple Myeloma (MM)1
3RecruitingTreatmentNeuroblastomas1
3RecruitingTreatmentNon-Hodgkin's Lymphoma (NHL)1
3RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
3RecruitingTreatmentSmall Cell Lung Carcinoma Extensive Disease1
3RecruitingTreatmentSoft Tissue Sarcoma (STS)1
3RecruitingTreatmentStage IIA Non-small Cell Lung Cancer / Stage IIB Non-small Cell Lung Cancer / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
3RecruitingTreatmentThymoma and Thymic Carcinoma1
3SuspendedTreatmentAcute Lymphoblastic Leukaemias (ALL) / B Acute Lymphoblastic Leukemia / Central Nervous System Leukemia / Cognitive Side Effects of Cancer Therapy / Neurotoxicity Syndrome / Osteonecrosis / Pain / Ph-Like Acute Lymphoblastic Leukemia / Testicular Leukemia / Therapy-Related Toxicity / Untreated Adult Acute Lymphoblastic Leukemia / Untreated Childhood Acute Lymphoblastic Leukemia1
3SuspendedTreatmentBrain Cancer / Choroid Plexus Tumors1
3TerminatedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
3TerminatedTreatmentExtensive Disease / First-Line / Lung Cancer Small Cell Lung Cancer (SCLC)1
3TerminatedTreatmentLeukemias1
3TerminatedTreatmentMalignant Lymphomas3
3TerminatedTreatmentMultiple Myeloma (MM)1
3TerminatedTreatmentRecurrent Diffuse Large B-Cell Lymphoma / Refractory Diffuse Large B-Cell Lymphoma1
3TerminatedTreatmentSarcomas1
3Unknown StatusTreatmentBrain and Central Nervous System Tumors2
3Unknown StatusTreatmentCancer, Ovarian / Childhood Germ Cell Tumor / Extragonadal Germ Cell Tumor1
3Unknown StatusTreatmentCarcinoma of Unknown Primary1
3Unknown StatusTreatmentCarcinoma, Small Cell1
3Unknown StatusTreatmentExtensive-Stage Small Cell Lung Cancer1
3Unknown StatusTreatmentExtragonadal Germ Cell Tumor / Teratoma / Testicular germ cell tumour1
3Unknown StatusTreatmentExtragonadal Germ Cell Tumor / Testicular germ cell tumour1
3Unknown StatusTreatmentIPI≥2 / Lymphoma, Large B-Cell, Diffuse (DLBCL)1
3Unknown StatusTreatmentLeukemias6
3Unknown StatusTreatmentLeukemias / Malignant Lymphomas1
3Unknown StatusTreatmentLeukemias / Mucositis / Oral Complications1
3Unknown StatusTreatmentLeukemias / Myelodysplastic Syndromes2
3Unknown StatusTreatmentLeukemias / Neutropenias1
3Unknown StatusTreatmentLocally Advanced and Metastatic Squamous Cell Carcinoma of the Lung / Lung Cancers / Squamous Cell Carcinoma of the Lung1
3Unknown StatusTreatmentLung Cancers5
3Unknown StatusTreatmentLymphoblastic Leukemia, Acute1
3Unknown StatusTreatmentLymphoma, Mantle-Cell1
3Unknown StatusTreatmentMalignant Lymphomas11
3Unknown StatusTreatmentNeuroblastomas5
3Unknown StatusTreatmentNonneoplastic Condition1
3Unknown StatusTreatmentRenal Cancers1
3Unknown StatusTreatmentRetinoblastoma1
3Unknown StatusTreatmentSarcomas3
3WithdrawnTreatmentExtensive-Stage Small Cell Lung Cancer1
3WithdrawnTreatmentSarcomas1
4CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4CompletedTreatmentAcute Lymphoblastic Leukaemias (ALL) / Stem Cell Transplantation, Hematopoietic1
4CompletedTreatmentAdult Acute Lymphocytic Leukemia2
4CompletedTreatmentBurkitt's Lymphoma / Large Cell Anaplastic Lymphoma / Lymphoma, Lymphoblastic / Mediastinal Neoplasms1
4CompletedTreatmentLymphoma, Lymphoblastic1
4RecruitingTreatmentALK-negative Anaplastic Large Cell Lymphoma / Angioimmunoblastic T Cell Lymphoma / Enteropathy Associated T Cell Lymphoma / Hepatosplenic T Cell Lymphoma / Peripherial T Cell Lymphoma,Not Otherwise Specified / Subcutaneous Panniculitis Like T Cell Lymphoma1
4RecruitingTreatmentAcute Lymphobkastic Leukemia1
4RecruitingTreatmentAcute Lymphoblastic Leukaemias (ALL)1
4RecruitingTreatmentCentral Nervous System Embryonal Tumors / Medulloblastomas1
4RecruitingTreatmentIntracranial Germ Cell Tumors1
4RecruitingTreatmentLung Cancer Small Cell Lung Cancer (SCLC)1
4RecruitingTreatmentMantle Cell Lymphoma (MCL)1
4RecruitingTreatmentPeripheral T Cell Lymphoma (PTCL)1
4Unknown StatusTreatmentAcute Myeloid Leukaemias (AML)1
4Unknown StatusTreatmentAdult Acute Lymphocytic Leukemia1
Not AvailableActive Not RecruitingTreatmentAdenocarcinoma of the Lung / Adenosquamous Cell Lung Cancer / Bronchoalveolar Cell Lung Cancer / Large Cell Lung Cancer / Squamous Cell Carcinoma of Lung / Stage IIIA Non-Small Cell Lung Cancer / Stage IIIB Non-Small Cell Lung Cancer1
Not AvailableActive Not RecruitingTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult Acute Myeloid Leukemia in Remission / Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities / Adult Acute Myeloid Leukemia With Del(5q) / Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) / Adult Acute Myeloid Leukemia With T(15;17)(q22;q12) / Adult Acute Myeloid Leukemia With T(16;16)(p13;q22) / Adult Acute Myeloid Leukemia With T(8;21)(q22;q22) / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Childhood Acute Lymphoblastic Leukemia in Remission / Childhood Acute Myeloid Leukemia in Remission / Childhood Burkitt Lymphoma / Childhood Diffuse Large Cell Lymphoma / Childhood Immunoblastic Large Cell Lymphoma / Childhood Nasal Type Extranodal NK/T-cell Lymphoma / Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor (PNET) / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Peripheral T-Cell Lymphoma (PTCL) / Plasma Cell Neoplasms / Primary Systemic Amyloidosis / Recurrent Adult Acute Lymphoblastic Leukemia / Recurrent Adult Acute Myeloid Leukemia / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Myeloid Leukemia / Recurrent Childhood Anaplastic Large Cell Lymphoma / Recurrent Childhood Grade III Lymphomatoid Granulomatosis / Recurrent Childhood Large Cell Lymphoma / Recurrent Childhood Lymphoblastic Lymphoma / Recurrent Childhood Small Noncleaved Cell Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Malignant Testicular Germ Cell Tumor / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Neuroblastoma / Recurrent Small Lymphocytic Lymphoma / Recurrent/Refractory Childhood Hodgkin Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Multiple Myeloma / Regional Neuroblastoma / Splenic Marginal Zone Lymphoma / Testicular Lymphoma / Unspecified Adult Solid Tumor, Protocol Specific / Unspecified Childhood Solid Tumor, Protocol Specific / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableActive Not RecruitingTreatmentHodgkins Disease (HD) / Malignant Lymphomas1
Not AvailableActive Not RecruitingTreatmentMalignant Lymphomas3
Not AvailableActive Not RecruitingTreatmentMedulloblastomas / Pinealoblastoma / Supratentorial Embryonal Tumor, Not Otherwise Specified / Untreated Childhood Medulloblastoma / Untreated Childhood Pineoblastoma / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
Not AvailableActive Not RecruitingTreatmentNon-Small-Cell Lung Carcinoma (NSCLC)1
Not AvailableActive Not RecruitingTreatmentPrimary Central Nervous System Neoplasms1
Not AvailableActive Not RecruitingTreatmentRecurrent Childhood Brain Tumor1
Not AvailableCompletedNot AvailableLung Cancer Small Cell Lung Cancer (SCLC)1
Not AvailableCompletedNot AvailableRecurrent Nasopharynx Carcinoma1
Not AvailableCompletedSupportive CareChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms1
Not AvailableCompletedSupportive CareMultiple Myeloma (MM)1
Not AvailableCompletedTreatmentAML1
Not AvailableCompletedTreatmentAcute Myeloid Leukaemias (AML)1
Not AvailableCompletedTreatmentAtaxia-Telangiectasia1
Not AvailableCompletedTreatmentBrain and Central Nervous System Tumors1
Not AvailableCompletedTreatmentBrain and Central Nervous System Tumors / Malignant Lymphomas1
Not AvailableCompletedTreatmentCancer, Ovarian / Sarcomas1
Not AvailableCompletedTreatmentChildhood Germ Cell Tumor / Extragonadal Germ Cell Tumor1
Not AvailableCompletedTreatmentDisseminated Neuroblastoma / Ganglioneuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableCompletedTreatmentEwing Sarcoma of Bone / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor1
Not AvailableCompletedTreatmentL1 Childhood Acute Lymphoblastic Leukemia / L2 Childhood Acute Lymphoblastic Leukemia / Non-T, Non-B Childhood Acute Lymphoblastic Leukemia / Recurrent Childhood Acute Lymphoblastic Leukemia / T-cell Childhood Acute Lymphoblastic Leukemia1
Not AvailableCompletedTreatmentLeukemias1
Not AvailableCompletedTreatmentLymphoma, Large B-Cell, Diffuse (DLBCL) / Post Transplant Lymphoproliferative Disorder / Primary Mediastinal (Thymic) Large B-cell Lymphoma1
Not AvailableCompletedTreatmentLymphoma, Large Cell / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableCompletedTreatmentLymphoma, Lymphoblastic1
Not AvailableCompletedTreatmentMalignant Lymphomas1
Not AvailableCompletedTreatmentProstate Cancer1
Not AvailableRecruitingTreatmentAIDS Related Non-Hodgkin Lymphoma / AIDS-Related Burkitt Lymphoma / AIDS-Related Diffuse Large B-cell Lymphoma / AIDS-Related Plasmablastic Lymphoma / AIDS-Related Primary Effusion Lymphoma / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableRecruitingTreatmentAcute Myeloid Leukaemias (AML)1
Not AvailableRecruitingTreatmentAdvanced Intra-Ocular Retinoblastoma / Retinoblastoma1
Not AvailableRecruitingTreatmentAtypical Teratoid/Rhabdoid Tumor (AT/RT) / CNS Tumors / Ewing's Family Tumors / Germ Cell Tumors / Hepatoblastomas / Medulloblastomas / Primary Malignant Brain Neoplasms / Renal Tumors / Retinoblastoma / Rhabdomyosarcomas / Soft Tissue Sarcoma (STS) / Supra-tentorial Primative Neuro-Ectodermal Tumor (PNET)1
Not AvailableRecruitingTreatmentClassical Hodgkins Lymphoma in Children and Adolescents1
Not AvailableRecruitingTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1
Not AvailableRecruitingTreatmentNeuroblastomas3
Not AvailableSuspendedTreatmentDisseminated Neuroblastoma / Localized Resectable Neuroblastoma / Localized Unresectable Neuroblastoma / Regional Neuroblastoma / Stage 4S Neuroblastoma1
Not AvailableTerminatedTreatmentAdult Acute Lymphoblastic Leukemia in Remission / Adult Grade III Lymphomatoid Granulomatosis / Adult Nasal Type Extranodal NK/T-Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Chronic Lymphocytic Leukemia / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableTerminatedTreatmentBruton's agammaglobulinemia / Chediak-Higashi Syndrome / Chronic Granulomatous Disease (CGD) / Common Variable Immunodeficiency / Familial Erythrophagocytic Lymphohistiocytosis / Graft Versus Host Disease (GVHD) / Immunologic Deficiency Syndromes / Leukocyte Adhesion Deficiency Syndrome / Lymphohistiocytosis, Hemophagocytic / Severe Combined Immunodeficiency / Virus-Associated Hemophagocytic Syndrome / Wiskott-Aldrich Syndrome (WAS) / X-Linked Hyper IgM Syndrome / X-Linked Lymphoproliferative Syndrome1
Not AvailableTerminatedTreatmentChronic Myeloproliferative Disorders / Graft Versus Host Disease (GVHD) / Leukemias / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Diseases / Sarcomas1
Not AvailableTerminatedTreatmentLymphohistiocytosis, Hemophagocytic1
Not AvailableUnknown StatusNot AvailableUnspecified Childhood Solid Tumor, Protocol Specific1
Not AvailableUnknown StatusTreatmentBrain and Central Nervous System Tumors / Cancer, Ovarian / Childhood Germ Cell Tumor / Extragonadal Germ Cell Tumor1
Not AvailableUnknown StatusTreatmentChediak-Higashi Syndrome / Familial Erythrophagocytic Lymphohistiocytosis / Graft Versus Host Disease (GVHD) / Lymphohistiocytosis, Hemophagocytic / Virus-Associated Hemophagocytic Syndrome / X-Linked Lymphoproliferative Syndrome1
Not AvailableUnknown StatusTreatmentLeukemias1
Not AvailableUnknown StatusTreatmentMalignant Lymphomas1
Not AvailableUnknown StatusTreatmentNeuroblastomas1
Not AvailableUnknown StatusTreatmentRetinoblastoma1
Not AvailableWithdrawnTreatmentAdult Nasal Type Extranodal NK/T-Cell Lymphoma / AIDS-Related Diffuse Large Cell Lymphoma / AIDS-Related Diffuse Mixed Cell Lymphoma / AIDS-Related Diffuse Small Cleaved Cell Lymphoma / AIDS-related Immunoblastic Large Cell Lymphoma / AIDS-Related Lymphoblastic Lymphoma / AIDS-related Peripheral/Systemic Lymphoma / AIDS-related Small Noncleaved Cell Lymphoma / Anaplastic Large Cell Lymphoma / Angioimmunoblastic T-Cell Lymphoma / Cutaneous B-Cell Non-Hodgkin Lymphoma / Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue / Hepatosplenic T-Cell Lymphoma / HIV-associated Hodgkin Lymphoma / Intraocular Lymphoma / Nodal marginal zone B-cell lymphomas / Noncutaneous Extranodal Lymphoma / Peripheral T-Cell Lymphoma (PTCL) / Recurrent Adult Burkitt Lymphoma / Recurrent Adult Diffuse Large Cell Lymphoma / Recurrent Adult Diffuse Mixed Cell Lymphoma / Recurrent Adult Diffuse Small Cleaved Cell Lymphoma / Recurrent Adult Grade III Lymphomatoid Granulomatosis / Recurrent Adult Hodgkin's Lymphoma / Recurrent Adult Immunoblastic Large Cell Lymphoma / Recurrent Adult Lymphoblastic Lymphoma / Recurrent Adult T-Cell Leukemia/Lymphoma / Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma / Recurrent Grade 1 Follicular Lymphoma / Recurrent Grade 2 Follicular Lymphoma / Recurrent Grade 3 Follicular Lymphoma / Recurrent Mantle Cell Lymphoma / Recurrent Marginal Zone Lymphoma / Recurrent Mycosis Fungoides/Sezary Syndrome / Recurrent Small Lymphocytic Lymphoma / Refractory Hairy Cell Leukemia / Small Intestine Lymphoma / Splenic Marginal Zone Lymphoma / Stage I AIDS-related Lymphoma / Stage II AIDS-related Lymphoma / Stage III AIDS-related Lymphoma / Stage IV AIDS-related Lymphoma / T-Cell Large Granular Lymphocyte Leukemia / Testicular Lymphoma / Waldenstrom's Macroglobulinemia (WM)1
Not AvailableWithdrawnTreatmentAdult Supratentorial Primitive Neuroectodermal Tumor (PNET) / Ewing Sarcoma of Bone / Extraosseous Ewing Sarcoma / Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor / Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1

Pharmacoeconomics

Manufacturers
  • Mylan pharmaceuticals inc
  • Bristol myers squibb co
  • Accord healthcare inc usa
  • App pharmaceuticals llc
  • Bedford laboratories div ben venue laboratories inc
  • Hospira inc
  • Marsam pharmaceuticals llc
  • Pharmachemie bv
  • Pierre fabre medicament
  • Teva parenteral medicines inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Injection, powder, lyophilized, for solutionIntravenous100 mg/1
CapsuleOral50 mg/1
InjectionIntravenous20 mg/mL
Injection, solutionIntravenous20 mg/mL
LiquidIntravenous20 mg
SolutionIntravenous20 mg
Injection, solution, concentrateIntravenous20 mg/mL
CapsuleOral50 mg
Prices
Unit descriptionCostUnit
VePesid 20 50 mg capsule Box1273.41USD box
Etopophos 100 mg vial159.55USD vial
Etoposide 50 mg capsule47.64USD capsule
Etoposide 100 mg/5 ml vial28.89USD ml
Toposar 100 mg/5 ml vial2.25USD ml
Toposar 1000 mg/50 ml vial1.12USD ml
Toposar 500 mg/25 ml vial1.06USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)236-251 °CPhysProp
water solubilitySparingly soluble FDA label
logP0.60HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.978 mg/mLALOGPS
logP0.73ALOGPS
logP1.16ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)9.33ChemAxon
pKa (Strongest Basic)-3.7ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count12ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area160.83 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity139.02 m3·mol-1ChemAxon
Polarizability58.77 Å3ChemAxon
Number of Rings7ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.836
Blood Brain Barrier-0.9609
Caco-2 permeable-0.5234
P-glycoprotein substrateSubstrate0.7019
P-glycoprotein inhibitor INon-inhibitor0.8005
P-glycoprotein inhibitor IINon-inhibitor0.8381
Renal organic cation transporterNon-inhibitor0.8412
CYP450 2C9 substrateNon-substrate0.8228
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6134
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.6884
CYP450 2D6 inhibitorNon-inhibitor0.8392
CYP450 2C19 inhibitorNon-inhibitor0.529
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5576
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9325
BiodegradationNot ready biodegradable0.9467
Rat acute toxicity2.9588 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9847
hERG inhibition (predictor II)Non-inhibitor0.8734
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004r-0090420000-e5d6bcd633116e0553a0
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004i-0190000000-ac64a57347a9295be5dc
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-004r-0590000000-e0e45774111103754c46
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-002r-0980000000-ccf595459b4b1988d77a
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-002r-0950000000-4d3313053107615d463a
Predicted LC-MS/MS Spectrum - 10V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 20V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 40V, PositivePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 10V, NegativePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 20V, NegativePredicted LC-MS/MSNot Available
Predicted LC-MS/MS Spectrum - 40V, NegativePredicted LC-MS/MSNot Available
1H NMR Spectrum1D NMRNot applicable
13C NMR Spectrum1D NMRNot applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as podophyllotoxins. These are tetralin lignans in which the benzene moiety of the tetralin skeleton is fused to a 1,3-dioxolane and the cyclohexane is fused to a butyrolactone (pyrrolidin-2-one).
Kingdom
Organic compounds
Super Class
Lignans, neolignans and related compounds
Class
Lignan lactones
Sub Class
Podophyllotoxins
Direct Parent
Podophyllotoxins
Alternative Parents
Aryltetralin lignans / Furanonaphthodioxoles / Tetralins / Pyranodioxins / Dimethoxybenzenes / Methoxyphenols / Benzodioxoles / Anisoles / Phenoxy compounds / Alkyl aryl ethers
show 14 more
Substituents
Podophyllotoxin / 1-aryltetralin lignan / Linear furanonaphthodioxole / Naphthofuran / Methoxyphenol / Pyranodioxin / Tetralin / M-dimethoxybenzene / Dimethoxybenzene / Benzodioxole
show 30 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organic heterotetracyclic compound, beta-D-glucoside, furonaphthodioxole (CHEBI:4911 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Ubiquitin binding
Specific Function
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segr...
Gene Name
TOP2A
Uniprot ID
P11388
Uniprot Name
DNA topoisomerase 2-alpha
Molecular Weight
174383.88 Da
References
  1. de Lucio B, Manuel V, Barrera-Rodriguez R: Characterization of human NSCLC cell line with innate etoposide-resistance mediated by cytoplasmic localization of topoisomerase II alpha. Cancer Sci. 2005 Nov;96(11):774-83. [PubMed:16271071 ]
  2. Lopez-Lazaro M, Pastor N, Azrak SS, Ayuso MJ, Austin CA, Cortes F: Digitoxin inhibits the growth of cancer cell lines at concentrations commonly found in cardiac patients. J Nat Prod. 2005 Nov;68(11):1642-5. [PubMed:16309315 ]
  3. Moneypenny CG, Shao J, Song Y, Gallagher EP: MLL rearrangements are induced by low doses of etoposide in human fetal hematopoietic stem cells. Carcinogenesis. 2006 Apr;27(4):874-81. Epub 2005 Dec 24. [PubMed:16377807 ]
  4. Uesaka T, Shono T, Kuga D, Suzuki SO, Niiro H, Miyamoto K, Matsumoto K, Mizoguchi M, Ohta M, Iwaki T, Sasaki T: Enhanced expression of DNA topoisomerase II genes in human medulloblastoma and its possible association with etoposide sensitivity. J Neurooncol. 2007 Sep;84(2):119-29. Epub 2007 Mar 15. [PubMed:17361331 ]
  5. Winnicka K, Bielawski K, Bielawska A: Cardiac glycosides in cancer research and cancer therapy. Acta Pol Pharm. 2006 Mar-Apr;63(2):109-15. [PubMed:17514873 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Inhibitor
General Function
Protein kinase c binding
Specific Function
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks.
Gene Name
TOP2B
Uniprot ID
Q02880
Uniprot Name
DNA topoisomerase 2-beta
Molecular Weight
183265.825 Da
References
  1. Azarova AM, Lyu YL, Lin CP, Tsai YC, Lau JY, Wang JC, Liu LF: Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies. Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11014-9. Epub 2007 Jun 19. [PubMed:17578914 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Kawashiro T, Yamashita K, Zhao XJ, Koyama E, Tani M, Chiba K, Ishizaki T: A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300. [PubMed:9732391 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Metabolizes several precarcinogens, drugs, and solvents to reactive metabolites. Inactivates a number of drugs and xenobiotics and also bioactivates many xenobiotic substrates to their hepatotoxic ...
Gene Name
CYP2E1
Uniprot ID
P05181
Uniprot Name
Cytochrome P450 2E1
Molecular Weight
56848.42 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inducer
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Wen Z, Tallman MN, Ali SY, Smith PC: UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos. 2007 Mar;35(3):371-80. Epub 2006 Dec 6. [PubMed:17151191 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Glutathione transferase activity
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Acts on 1,2-epoxy-3-(4-nitrophenoxy)propane, phenethylisothiocyanate 4-nitrobenzyl chlorid...
Gene Name
GSTT1
Uniprot ID
P30711
Uniprot Name
Glutathione S-transferase theta-1
Molecular Weight
27334.755 Da
References
  1. Mans DR, Lafleur MV, Westmijze EJ, Horn IR, Bets D, Schuurhuis GJ, Lankelma J, Retel J: Reactions of glutathione with the catechol, the ortho-quinone and the semi-quinone free radical of etoposide. Consequences for DNA inactivation. Biochem Pharmacol. 1992 Apr 15;43(8):1761-8. [PubMed:1315544 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
S-nitrosoglutathione binding
Specific Function
Conjugation of reduced glutathione to a wide number of exogenous and endogenous hydrophobic electrophiles. Regulates negatively CDK5 activity via p25/p35 translocation to prevent neurodegeneration.
Gene Name
GSTP1
Uniprot ID
P09211
Uniprot Name
Glutathione S-transferase P
Molecular Weight
23355.625 Da
References
  1. Mans DR, Lafleur MV, Westmijze EJ, Horn IR, Bets D, Schuurhuis GJ, Lankelma J, Retel J: Reactions of glutathione with the catechol, the ortho-quinone and the semi-quinone free radical of etoposide. Consequences for DNA inactivation. Biochem Pharmacol. 1992 Apr 15;43(8):1761-8. [PubMed:1315544 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and...
Gene Name
PTGS2
Uniprot ID
P35354
Uniprot Name
Prostaglandin G/H synthase 2
Molecular Weight
68995.625 Da
References
  1. Haim N, Roman J, Nemec J, Sinha BK: Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20. [PubMed:3006680 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Haim N, Roman J, Nemec J, Sinha BK: Peroxidative free radical formation and O-demethylation of etoposide(VP-16) and teniposide(VM-26). Biochem Biophys Res Commun. 1986 Feb 26;135(1):215-20. [PubMed:3006680 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocyte...
Gene Name
ABCC3
Uniprot ID
O15438
Uniprot Name
Canalicular multispecific organic anion transporter 2
Molecular Weight
169341.14 Da
References
  1. Zeng H, Chen ZS, Belinsky MG, Rea PA, Kruh GD: Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32. [PubMed:11585759 ]
  2. Zehnpfennig B, Urbatsch IL, Galla HJ: Functional reconstitution of human ABCC3 into proteoliposomes reveals a transport mechanism with positive cooperativity. Biochemistry. 2009 May 26;48(20):4423-30. doi: 10.1021/bi9001908. [PubMed:19334674 ]
  3. Zelcer N, Saeki T, Reid G, Beijnen JH, Borst P: Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). J Biol Chem. 2001 Dec 7;276(49):46400-7. [PubMed:11581266 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Transporter activity
Specific Function
Isoform 1: May participate directly in the active transport of drugs into subcellular organelles or influence drug distribution indirectly. Transports glutathione conjugates as leukotriene-c4 (LTC4...
Gene Name
ABCC6
Uniprot ID
O95255
Uniprot Name
Multidrug resistance-associated protein 6
Molecular Weight
164904.81 Da
References
  1. Cai J, Daoud R, Alqawi O, Georges E, Pelletier J, Gros P: Nucleotide binding and nucleotide hydrolysis properties of the ABC transporter MRP6 (ABCC6). Biochemistry. 2002 Jun 25;41(25):8058-67. [PubMed:12069597 ]
  2. Belinsky MG, Chen ZS, Shchaveleva I, Zeng H, Kruh GD: Characterization of the drug resistance and transport properties of multidrug resistance protein 6 (MRP6, ABCC6). Cancer Res. 2002 Nov 1;62(21):6172-7. [PubMed:12414644 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Gao J, Murase O, Schowen RL, Aube J, Borchardt RT: A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells. Pharm Res. 2001 Feb;18(2):171-6. [PubMed:11405287 ]
  2. Polli JW, Wring SA, Humphreys JE, Huang L, Morgan JB, Webster LO, Serabjit-Singh CS: Rational use of in vitro P-glycoprotein assays in drug discovery. J Pharmacol Exp Ther. 2001 Nov;299(2):620-8. [PubMed:11602674 ]
  3. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MDR1 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):765-72. [PubMed:12134945 ]
  4. Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
  5. Nagy H, Goda K, Fenyvesi F, Bacso Z, Szilasi M, Kappelmayer J, Lustyik G, Cianfriglia M, Szabo G Jr: Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies. Biochem Biophys Res Commun. 2004 Mar 19;315(4):942-9. [PubMed:14985103 ]
  6. Guo A, Marinaro W, Hu P, Sinko PJ: Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63. [PubMed:11901101 ]
  7. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Transporter activity
Specific Function
Mediates export of organic anions and drugs from the cytoplasm. Mediates ATP-dependent transport of glutathione and glutathione conjugates, leukotriene C4, estradiol-17-beta-o-glucuronide, methotre...
Gene Name
ABCC1
Uniprot ID
P33527
Uniprot Name
Multidrug resistance-associated protein 1
Molecular Weight
171589.5 Da
References
  1. Heijn M, Hooijberg JH, Scheffer GL, Szabo G, Westerhoff HV, Lankelma J: Anthracyclines modulate multidrug resistance protein (MRP) mediated organic anion transport. Biochim Biophys Acta. 1997 May 22;1326(1):12-22. [PubMed:9188796 ]
  2. Guo A, Marinaro W, Hu P, Sinko PJ: Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63. [PubMed:11901101 ]
  3. Godinot N, Iversen PW, Tabas L, Xia X, Williams DC, Dantzig AH, Perry WL 3rd: Cloning and functional characterization of the multidrug resistance-associated protein (MRP1/ABCC1) from the cynomolgus monkey. Mol Cancer Ther. 2003 Mar;2(3):307-16. [PubMed:12657726 ]
  4. Nunoya K, Grant CE, Zhang D, Cole SP, Deeley RG: Molecular cloning and pharmacological characterization of rat multidrug resistance protein 1 (mrp1). Drug Metab Dispos. 2003 Aug;31(8):1016-26. [PubMed:12867490 ]
  5. Stride BD, Grant CE, Loe DW, Hipfner DR, Cole SP, Deeley RG: Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol. 1997 Sep;52(3):344-53. [PubMed:9281595 ]
  6. Wong IL, Chan KF, Tsang KH, Lam CY, Zhao Y, Chan TH, Chow LM: Modulation of multidrug resistance protein 1 (MRP1/ABCC1)-mediated multidrug resistance by bivalent apigenin homodimers and their derivatives. J Med Chem. 2009 Sep 10;52(17):5311-22. doi: 10.1021/jm900194w. [PubMed:19725578 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Atpase activity, coupled to transmembrane movement of substances
Specific Function
ATP-dependent transporter probably involved in cellular detoxification through lipophilic anion extrusion.
Gene Name
ABCC10
Uniprot ID
Q5T3U5
Uniprot Name
Multidrug resistance-associated protein 7
Molecular Weight
161627.375 Da
References
  1. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD: Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol. 2003 Feb;63(2):351-8. [PubMed:12527806 ]
  2. Hopper-Borge E, Xu X, Shen T, Shi Z, Chen ZS, Kruh GD: Human multidrug resistance protein 7 (ABCC10) is a resistance factor for nucleoside analogues and epothilone B. Cancer Res. 2009 Jan 1;69(1):178-84. doi: 10.1158/0008-5472.CAN-08-1420. [PubMed:19118001 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Tang F, Horie K, Borchardt RT: Are MDCK cells transfected with the human MRP2 gene a good model of the human intestinal mucosa? Pharm Res. 2002 Jun;19(6):773-9. [PubMed:12134946 ]
  2. Guo A, Marinaro W, Hu P, Sinko PJ: Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63. [PubMed:11901101 ]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S, Baba M: Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 2003 Jan;63(1):65-72. [PubMed:12488537 ]
  2. Allen JD, Van Dort SC, Buitelaar M, van Tellingen O, Schinkel AH: Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Res. 2003 Mar 15;63(6):1339-44. [PubMed:12649196 ]
Drug created on June 13, 2005 07:24 / Updated on September 01, 2017 10:31